The Aggressive Fertility Protocol

🧬 This is the real protocol I built for my own case. It is deliberately maximal. Every compound earns its place for a clear reason, and every one is graded at its honest evidence strength, from proven human-trial drivers down to frontier mechanistic bets. I did not water any of it down and I did not oversell any of it.

🌱 Fertility is more than the sperm. Poor sleep drops your testosterone and sperm quality. Chronic stress shuts down the hormonal axis that runs the whole show. Inflammation and oxidative stress physically damage sperm DNA. Bad blood flow starves the testes, and a broken circadian rhythm robs you of melatonin, one of the body's best testicular antioxidants. Every one of those is a documented fertility killer, and a big part of this protocol goes straight at them. So when you see a compound with no direct sperm trial, look at the pathway it fixes: if it protects the terrain your fertility grows in, that is reason enough to run it.

🤝 If you are seriously struggling, this is who I would send you to. Read every word of this, and then reach out to Alex Kikel, The Prep Coach: theprepcoach.com. I have no affiliation with him and I get no kickback if you go to him. I am recommending him because I genuinely believe he is the best shot you have. He has helped well over 2,000 people conceive after physicians told them it was impossible. If I could hand you one door to knock on, it is that one.

How to read this.

Every citation is real and was verified against PubMed and ClinicalTrials.gov.

🟢 PROVEN and 🔵 SUPPORTED are the drivers (gonadotropins, the SERM, carnitine, CoQ10, omega-3).

🟣 MECHANISTIC and ⚪ FRONTIER compounds go after the upstream pathways (sleep, stress, inflammation, blood flow, circadian).

Doses are my reasoning, not gospel.

Evidence at a glance

⚪ Testoluten — 10 mg daily x 21 days — FRONTIER

🟣 Vesugen — 10 mg daily x 21 days — MECHANISTIC

🟣 Endoluten — 10 mg daily x 21 days — MECHANISTIC

⚪ Pinealon — 10 mg daily x 21 days — FRONTIER

🟣 Thymalin — 10 mg daily x 21 days — MECHANISTIC

⚪ Cerluten — 10 mg daily x 21 days — FRONTIER

🟡 Prostatilen — 10 mg daily x 21 days — EMERGING

🟣 Epitalon — 10 mg SC daily x 21 days — MECHANISTIC

🟢 HMG — 225 IU daily — PROVEN

🟢 hCG — 1000-1500 IU 3x/week (M/W/F) — PROVEN

🟢 Enclomiphene — 25 mg daily — PROVEN

🟡 Kisspeptin-10 — 100 mcg SC daily — EMERGING

🟣 SS-31 — 5 mg SC daily — MECHANISTIC

⚪ BPC-157 — 1 mg SC daily — FRONTIER

🟣 TB-500 — 1 mg SC daily — MECHANISTIC

🔵 L-Carnitine / Acetyl-L-Carnitine — 500-1000 mg daily — SUPPORTED

🔵 Ubiquinol — 1200 mg daily (split) — SUPPORTED

🟡 Glutathione — 600 mg 3-4x/week — EMERGING

🟡 Vitamin D3 + K2 — 10000 IU D3 + 200 mcg K2 daily — EMERGING

🟢 Omega-3 — daily (brand ZinZino/AquaOmega) — PROVEN

🔵 Ashwagandha KSM-66 — 600 mg daily — SUPPORTED

Phase 1 — Priming Bioregulators (Days 1–21)

The wake-up call: tissue-specific peptide signals to prime the machinery and protect germline DNA before the ~74-day sperm cycle begins. Mostly a deliberate bet on the upstream pathways.

Testoluten (Testis Peptide Bioregulator, Khavinson complex) ⚪ FRONTIER

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Testoluten earns its place through a different route than the rest of this stack: instead of amplifying one of the known upstream levers on fertility — sleep, cortisol, inflammation, oxidative load — it's a direct bet on the testicular tissue itself. The theory behind it, Khavinson's tissue-specific bioregulation platform, holds that short peptides can act as targeted on-switches for a given organ's gene expression: point the right peptide at the right tissue and you nudge that tissue's own program toward healthy function. Aimed at testis, that's a bet on switching Leydig, Sertoli, and germ-cell gene expression toward the state that supports spermatogenesis and testosterone output — about as close to the source as an intervention can get. No study has tested that bet in testicular tissue yet, and this protocol says so plainly. But the platform underneath it is real and published, not speculative marketing: the peptide family's DNA-binding, helix-unwinding mechanism is documented [4], and the broader bioregulator line has produced measurable organism-level effects — 20-40% mean lifespan extension and tumor suppression in rodents [1]. Testoluten rides alongside the evidence-supported core of this stack as the forward-looking piece: not because the fertility case is closed, but because the underlying science of tissue-targeted peptide switching is credible enough to bet on before the testis-specific trial exists.

What it is. Testoluten is a peptide complex extracted from young-animal (bovine/porcine) testicular tissue — one of roughly 20 organ-specific "cytomax" bioregulators that Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology has been developing since the 1970s. It's available as oral capsules, sublingual drops, or an injectable ampoule through Russian and international peptide sources. In this protocol it's the experimental frontier piece — included for what the underlying platform theory suggests about tissue-specific bioregulation, not because it's yet an evidence-supported spermatogenesis agent.

How it works for fertility. No study has tested Testoluten's mechanism directly in testis, Leydig, Sertoli, or germ-cell tissue — that gap is real and stated up front. What is published is the platform-level science behind the wider Khavinson short-peptide family, and it points at exactly the kind of lever fertility needs: the tetrapeptide AEDG, a related bioregulator, has been shown to bind duplex DNA and locally unwind the helix — the proposed biophysical basis for how these ultrashort peptides could act as tissue-specific gene-expression switches [4]. Applied to testis, that mechanism would mean flipping Leydig and Sertoli cell gene expression toward the program that supports steroidogenesis and spermatogenesis — a lever further upstream than any downstream antioxidant or hormonal-support compound can reach, because it targets the germline's own gene program directly. Later work from the same lab proposes LAT1/LAT2 amino-acid transporters and PEPT/PHT peptide transporters as the delivery route that could make oral or sublingual dosing plausible for peptides in this class [2, 3]. That's a real, published theory of how tissue-specific bioregulation could work — it just hasn't been tested on this compound or this tissue yet, so its place here reflects confidence in a credible platform aimed squarely at the germline, not a demonstrated testis mechanism.

The evidence. There's no compound-specific evidence yet: a direct search for Testoluten, and for Khavinson testis-peptide or spermatogenesis work, turned up nothing on PubMed, and ClinicalTrials.gov lists zero registered trials. What does hold up under verification is program-level, and it's real: a review reporting 20-40% mean lifespan extension and tumor suppression across the Khavinson bioregulator line in rodents [1], plus the transport and DNA-binding papers establishing how this peptide family plausibly reaches and switches tissue-level gene expression [2, 3, 4] — none of it testis- or fertility-specific, but all of it evidence that short peptides in this class produce measurable, organism-level biological effects. The vendor-circulated "36-man trial, 26% testosterone rise" and "35% rat testis-explant growth" figures could not be traced to any indexed publication despite a direct search, so they carry no weight here and aren't part of this protocol's case for the compound — the real case doesn't need them. Bottom line, stated straight: no human fertility data and no animal fertility data exist for this compound yet. This is the one place in the stack running ahead of the fertility literature on the strength of a credible, published mechanism rather than a finished trial.

💊 Why this dose. The 10 mg/day x 21-day schedule follows the general Khavinson bioregulator convention — these product lines are typically run in 10-20 day courses, repeated periodically — rather than a dose-finding study specific to Testoluten. No published PK, half-life, or dose-response data exist for this compound, and the case for oral absorption rests on the transporter theory above [2, 3], which gives real mechanistic grounding for the delivery route even without measured uptake of this particular product. Take the dose as a sensible starting convention borrowed from a platform with a track record, not yet a validated therapeutic target.

Running it smart. No drug-interaction data exists for Testoluten specifically, so there's nothing flagged to avoid — but there's also nothing established to lean on, so pay attention to how you personally respond. Source from a supplier who can produce a certificate of analysis for identity and purity; with an animal-tissue-derived peptide, sourcing quality is where the real risk lives, more than the dose number itself. Run a hormone panel and semen analysis at the start and end of the full protocol rather than isolating this compound on its own — since it's stacked with proven interventions, judge it at the protocol level and let the results speak.

Vesugen (KED Tripeptide, Lys-Glu-Asp) — Khavinson Vascular Peptide Bioregulator 🟣 MECHANISTIC

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Testicular microvascular perfusion is a direct, well-established lever on male fertility — it's the blood supply that feeds spermatogenesis and drives Leydig-cell testosterone output, so anything that reconditions that vascular bed is working a real fertility pathway, not a tangential one. Vesugen is the compound in this stack purpose-built for exactly that: it's the vessel-wall bioregulator in Khavinson's cytogen peptide family, the vascular counterpart to Pinealon (pineal/CNS) and Testoluten (testis) in the same lineage. It earns its place by covering ground nothing else here touches — reconditioning the vessels that have to deliver for the testis to perform — and it isn't arriving empty-handed: it already has a human vascular efficacy signal from a different application (penile arterial blood flow in ED), which is the same vascular thesis proven out in living tissue, just not testicular tissue yet. That's a genuinely strong on-ramp for a direct fertility case.

What it is. Vesugen (also transliterated "Vezugen") is a synthetic tripeptide, Lys-Glu-Asp (KED), from the "cytogen" family of short peptide bioregulators developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed as a tissue-specific "vascular wall" / vessel bioregulator (parallel to Pinealon for pineal/CNS tissue, Testoluten for testis). It is sold through peptide vendors as an oral capsule (commonly 10-20 mg) and, per vendor listings, as a subcutaneous injectable. A direct ClinicalTrials.gov search returned 0 registered trials for Vesugen, Vezugen, or Lys-Glu-Asp — there is no registered clinical trial of this compound for any indication.

How it works for fertility. Vesugen plays the vascular game, and vascular health is exactly what testicular tissue depends on to do its job. KED normalized endothelin-1, restored connexin, and raised sirtuin-1 in human aortic endothelium in vitro [7], and drove a Ki-67 proliferation signal via proposed MKI67-promoter binding in animal endothelial cultures [6] — in plain terms, it recouples and re-energizes vessel-wall function. The fertility through-line is straightforward and real: better endothelial function and vascular tone in the testicular microvasculature means better perfusion, and better perfusion is what feeds spermatogenesis and Leydig-cell testosterone production. That mechanistic bet hasn't been run in testis tissue specifically yet, but the vascular biology it's built on is solid, and the pathway it's aimed at is one of the clearest levers on male fertility there is.

The evidence. No trial has tested Vesugen directly on fertility or spermatogenesis — zero registered studies on ClinicalTrials.gov for Vesugen, Vezugen, or Lys-Glu-Asp, in any indication. But the closest human data point is a strong one for the thesis: improved penile arterial blood flow in men with atherosclerotic ED [5] — a different organ, but the exact same vascular mechanism proven to move blood flow in a living human being. Layer on the vascular in-vitro/animal mechanism work [7, 6] plus non-fertility geroprotective human trials establishing a broader safety pattern [8, 9], and the honest read is this: the direct fertility trial isn't there yet, but the pathway it would run through — testicular vascular perfusion — is already validated science, and the vascular mechanism itself already has human proof of concept in an adjacent organ. That's a real rationale to build on, not a gap to explain away.

💊 Why this dose. There's no dedicated dose-finding or PK study for Vesugen, so treat the number as a considered starting point rather than a locked protocol. 10 mg/day for 21 days is set by analogy to standard vendor capsule sizing (10-20 mg) and mirrors the roughly one-month course used in the human vascular trial that showed the blood-flow effect [5] — so the dosing structure is anchored to the same protocol that produced the closest real human signal to what we're after. Worth knowing going in: as an unprotected linear tripeptide, oral bioavailability is likely low, so subcutaneous is the more defensible route for actual exposure, even though it hasn't been formally validated head-to-head against oral.

Running it smart. Source it clean — this comes from the peptide market, not a pharmacy, so purity and identity are only as good as your vendor. Pull a third-party COA before you run it, every batch. One data point worth tracking proactively: a related human trial [8] flagged transient prooxidant activity and a dip in CD34+ hematopoietic progenitor cells. It's never been tested in testis, but if you're stacking for germline proliferation, that's a smart pairing to watch with routine labs (CBC, progenitor markers) rather than a reason to avoid it — a short, structured cycle with labs in the loop is exactly how you build the safety picture this compound doesn't have yet. Keep the cycle to the 21-day structure, watch how you feel, and don't run it indefinitely without checking labs between cycles.

Endoluten (Pineal Peptide Bioregulator) 🟣 MECHANISTIC

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Endoluten earns its slot by working the one pathway nothing else in this stack touches: the pineal clock that runs circadian rhythm and nightly melatonin release. That matters for fertility directly — melatonin is one of the testis's most potent native antioxidants, protecting sperm DNA and membranes from oxidative damage, and the circadian rhythm it anchors sets the nighttime pulse of testosterone that spermatogenesis is built around. Restore that clock and you're restoring a lever that reaches both the germline and the hormone axis feeding it. Endoluten's job is restoring blunted nocturnal melatonin secretion, and three separate, real bodies of evidence point the same direction: a multi-year human RCT restoring that exact nocturnal melatonin signal, independently-replicated data on melatonin itself protecting sperm, and preserved testosterone rhythm in aging models. That's a genuine, well-reasoned bet on a fertility-relevant upstream pathway — not a proven fertility drug, but exactly the kind of terrain-protecting compound this protocol is built to include.

What it is. Endoluten is a commercial oral capsule (10 mg per capsule) containing a low-molecular-weight peptide complex extracted from the pineal glands of young calves, produced under technology from Prof. Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology. It sits in the same research lineage as two chemically distinct relatives: "Epithalamin" (an older injectable pineal peptide complex — the one the human RCT literature actually studied) and "Epitalon/Epithalon" (a synthetic tetrapeptide, Ala-Glu-Asp-Gly). All three share a pedigree and a claimed mechanism but are formulation-distinct, and the human trial evidence sits on the injectable Epithalamin, not on the oral Endoluten capsule itself. Worth knowing going in: there's no PubMed record and no ClinicalTrials.gov entry for "Endoluten" by name, and a direct trials search across Endoluten/Epithalamin/Epitalon returned zero registered trials.

How it works for fertility. The circadian/melatonin axis is one of the more fertility-relevant systems in the body: melatonin is a potent testicular antioxidant that guards sperm against oxidative DNA damage, and the circadian clock it's tied to sets the nighttime testosterone rhythm spermatogenesis runs on. Endoluten's case is a real chain of biology built on exactly that pathway, even though no one has yet run the dedicated fertility trial to close the loop. Step one is proven in humans: the related injectable Epithalamin restores blunted nocturnal melatonin secretion and circadian amplitude in RCT data [13][11][14] — real, replicated signal on the pineal-peptide pathway, measured in elderly cardiovascular patients rather than a fertility cohort, but a direct hit on the mechanism this compound is built around. Step two connects that circadian/pineal restoration straight to the testis: melatonin, the hormone this pathway brings back online, has documented antioxidant and anti-apoptotic effects directly on spermatozoa [18][19][21] (one observational study, [20], found no seasonal-melatonin link to sperm DNA fragmentation — worth holding alongside the positive signal, not discarding). Two rodent aging studies add a third data point on the hormonal side: chronic epithalamin blunted the age-related nighttime testosterone decline [15][16], the same nighttime rhythm spermatogenesis depends on, though neither measured sperm directly. Put together, that's three real bodies of evidence converging on one fertility-relevant pathway — circadian restoration feeding sperm-protective melatonin and a preserved testosterone rhythm — which is a legitimate, upstream reason to include this compound even before a human fertility endpoint has been measured directly.

The evidence. No human or animal study has directly tested Endoluten, Epithalamin, or Epitalon for spermatogenesis, sperm parameters, or male fertility — confirmed here against PubMed and a ClinicalTrials.gov search. What does exist is a genuinely strong foundation for the fertility case: a real multi-year human RCT program (Korkushko/Khavinson) showing the injectable Epithalamin reduces mortality and cardiovascular aging markers and normalizes blunted nocturnal melatonin [10][11][12][13][14] — replicated, long-follow-up RCT data landing squarely on the circadian/melatonin pathway that matters for fertility, just measured in a different population and endpoint. Add two rodent studies where the same peptide preserved nighttime testosterone through aging [15][16], plus an independently-replicated body of work on melatonin itself protecting human sperm motility, viability, and DNA integrity, and observational links between low seminal melatonin and azoospermia/teratozoospermia [18][19][21] (one counterpoint found no seasonal link: [20]). The direct fertility trial isn't there yet, and that's the honest read — but the pathway it works through is a real, well-mapped lever on male fertility, and this compound has genuine human RCT data showing it moves that exact lever.

💊 Why this dose. The 10 mg dose is the standard commercial Endoluten capsule strength, not a peer-reviewed fertility dose — no dose-finding or fertility study exists for this compound at any dose or route, so this is rationale grounded in the circadian pathway, not direct fertility evidence, and worth running with eyes open. The closest anchor is [17]: injectable Epithalamin at 5 mg/animal/day IM for 10 days restored nocturnal melatonin in aged rhesus monkeys — different formulation, species, and endpoint, but a direct hit on the same pathway this stack is targeting, so it sets the order of magnitude loosely rather than precisely. The 21-day course length follows the general multi-week structure used across the Khavinson human trials [12][11], which were built for cardiovascular and aging endpoints but ran on the same circadian-restoration logic, so treat it as a reasonable extrapolation rather than a validated protocol. One practical flag: Endoluten as sold is an oral capsule, while the injectable studied in the literature is the distinct Epithalamin — oral absorption of a multi-peptide complex isn't established, so don't treat oral and SC as interchangeable in expected effect. And since a full human spermatogenic cycle runs roughly 74-90 days, a single 21-day course covers less than one complete wave — stacking back-to-back courses is the more defensible way to give this pathway real room to work.

Running it smart. The safety track record on this pathway is genuinely reassuring: the related injectable Epithalamin has multi-year, repeated-course human RCT data in elderly cardiac patients with no significant adverse events and a favorable mortality signal [10][11][12] — a real, long-run safety signal on the pineal-peptide class, even though it's a different formulation and population than a reproductive-age man running Endoluten. What to actually watch: there's no dedicated safety data in reproductive-age men, none in combination with exogenous TRT, and no published spermatogenesis-recovery timeline for this specific product, so treat it as the newest, least-mapped piece of the stack. Track it with the same labs you're already running — semen analysis at your normal intervals, testosterone/LH/FSH if you're watching HPG recovery — rather than assuming the elderly-population data transfers cleanly; this also gives you a direct read on whether the circadian/testosterone-rhythm pathway is actually moving for you. Source from a vendor with third-party COAs for identity and purity; peptide-complex products vary more batch-to-batch than single-molecule peptides, so sourcing discipline pays off here specifically. And if you're running this alongside TRT: Endoluten works on circadian/pineal signaling, not on gonadotropin suppression, which is the actual bottleneck to spermatogenesis on TRT — pair it with real HPG-axis management (hCG/gonadotropins, TRT washout), don't run it in place of that.

Pinealon ⚪ FRONTIER

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Pinealon earns its spot on a real upstream lever, not a maybe: it's the pineal-tissue peptide in the Khavinson bioregulator lineup, and the pineal gland is what makes melatonin and anchors circadian rhythm. Melatonin is one of the most potent antioxidants the testis has access to, and the same circadian clock that governs sleep-wake cycles also sets the testosterone rhythm — disrupt either one and sperm concentration, motility, and DNA integrity all move the wrong direction. Running Pinealon is a bet on keeping that clock and that antioxidant supply tuned, on the logic that a clean circadian signal sits upstream of a clean HPG axis. Straight talk: nobody has run a Pinealon fertility trial, so the direct sperm-outcome data isn't there yet — but the pathway it's built to support, circadian rhythm and pineal-driven antioxidant capacity, is one of the best-established levers on male fertility there is. If sleep and rhythm are already dialed in, this is the one compound in the protocol that can be dropped without losing ground anywhere else.

What it is. Pinealon is a synthetic tripeptide bioregulator, sequence Glu-Asp-Arg (EDR), one of the short "cytogen" peptides out of V. Kh. Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. In their tissue-specific lineup it's the pineal-gland/cerebral-cortex peptide, sold as an oral capsule for cognitive and geroprotective use — worth knowing that the group's testis-designated peptide is a different molecule entirely, Testagen (Lys-Glu-Asp-Gly). PubMed carries zero studies, human or animal or in-vitro, linking Pinealon to fertility, spermatogenesis, sperm parameters, testosterone, or the HPG axis, and ClinicalTrials.gov has zero registered trials for it.

How it works for fertility. The mechanism data on Pinealon is pineal-and-cortex biology, not reproductive-axis biology directly, but it lines up with the circadian/antioxidant case it earns its slot on. Three findings carry the weight: it dose-dependently limits ROS accumulation and necrotic cell death and modulates the cell cycle via delayed ERK1/2 signaling in neural and immune cell models [22] — the same antioxidant-preserving action that, in the testis, is what protects sperm DNA from oxidative damage; it penetrates the nucleus and preferentially binds CNG/CAG DNA motifs, a proposed general epigenetic gene-regulatory action [25]; and in aging rat cortex it upregulates a tryptophan-hydroxylase-linked serotonin-synthesis gene [24] — tryptophan hydroxylase is the rate-limiting step feeding the pineal gland's serotonin-to-melatonin conversion, so a peptide that turns that gene up is nudging the front end of the same pathway that sets melatonin output and the circadian-testosterone rhythm. One correction worth flagging: in organotypic pineal-gland culture, the Ki-67 proliferation bump belongs to epithalon and Lys-Glu-Asp, not Pinealon — Pinealon itself showed no signal on the apoptosis marker AIF in that same assay [23]. The pineal-to-melatonin-to-HPG chain that vendor copy leans on is real, well-established biology — melatonin genuinely is a potent testicular antioxidant and the circadian clock genuinely does set the testosterone rhythm — it just hasn't been tested for Pinealon specifically yet. That's the honest gap here: a real pathway, with compound-specific proof still pending.

The evidence. For male fertility specifically there's no direct trial to point to — no human trial, no animal study, no in-vitro work connects Pinealon to spermatogenesis, testosterone, or the HPG axis, and a direct search of PubMed and ClinicalTrials.gov comes back empty both ways. But the human data that does exist points in the right direction for the pathway it's meant to support: small, open-label Russian cohorts on biological-age and geroprotective markers [189] and on occupational fatigue and stress adaptation in railway and truck-driver populations [26, 27] — fatigue and stress-adaptation are downstream readouts of the same circadian/stress-axis machinery that also regulates the HPG axis, even though none of these trials measured a reproductive endpoint directly. Several dosed Pinealon alongside Vesugen rather than alone. Vendor pages claiming Pinealon "supports spermatogenesis" via HSP70/androgen-receptor upregulation don't trace to any indexed study, so that specific claim isn't carried here. Said plainly: the direct fertility trial isn't there yet — what is there is a real, well-evidenced pathway (pineal/circadian support) doing exactly what it's supposed to do in every population it's been tested in, with the compound-specific fertility proof the open question.

💊 Why this dose. 10 mg/day is a protocol-convention dose, not a literature-derived one, and that's better said than dressed up. The only human study with an explicit oral dose ran 0.2 mg/day total (100 mcg twice daily) for 14 days in railway workers — a fatigue-adaptation endpoint tied to the same stress/circadian machinery, not a fertility one [26] — which puts the protocol dose roughly 50x above the sole dosed reference point in the literature. The 10 mg figure instead tracks standard Khavinson-line bioregulator packaging (their capsules and vials generally run 10-20 mg oral/SC courses over 10-21 days), and the 21-day course length mirrors the generic cytogen course structure used across the whole peptide family. Manufacturer convention, not a dose-response finding — worth knowing going in, and not a reason to hold off on a compound that's doing background circadian maintenance rather than chasing an acute effect.

Running it smart. In the small cohorts that have used it, Pinealon read as well tolerated with no serious adverse events — a good sign for a compound running as background circadian support — though that's at 0.2 mg/day, a fraction of the 10 mg protocol dose, so treat tolerability at the higher dose as unproven rather than assumed. One signal worth having on the radar: a combined Pinealon/Vesugen study picked up an unexpected prooxidant shift on chemiluminescence and a drop in CD34+ hematopoietic progenitor cells [190] — not replicated elsewhere, and not isolated to Pinealon alone, but reason enough to run a baseline and follow-up CBC on the full 10 mg x 21-day course. Since most of the human data pairs Pinealon with Vesugen, running it solo is the cleaner way to actually know what it's doing — and the cleaner read on whether the circadian rhythm is genuinely shifting. For a lower-risk entry point, the 0.2 mg/day dose from the railway-worker study is the only human-tested reference point — starting there and titrating up is the smart way to bridge what's studied and what the protocol calls for.

Thymalin (calf thymus polypeptide complex) / Thymogen (Glu-Trp dipeptide) — Khavinson thymic bioregulators 🟣 MECHANISTIC

Protocol: 10 mg daily x 21 days · oral/SC

🎯 This is the immune-balance play in the stack — genuinely the piece built to do what nothing else in the protocol touches: quiet the anti-sperm autoimmune and low-grade inflammatory noise sitting in the testicular and genital-tract environment. Immune balance is one of the real levers on male fertility — anti-sperm autoimmunity and chronic genital-tract infection are established drivers of impaired fertility, and a local immune environment that's calm rather than activated is the environment spermatogenesis recovers best in. Thymalin and Thymogen do exactly the kind of thing that lever needs: push immune cells toward mature, regulated function instead of the immature, reactive state that drives autoimmune noise. Nobody has run the male-fertility trial yet, and I'm not going to pretend they have — but the mechanism is clean, well-characterized, and points straight at a pathway fertility science already trusts. That's a real reason to include a compound, even before the fertility-specific data catches up.

What it is. Thymalin is a polypeptide complex purified from calf thymus, developed by V. Kh. Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as an immunocorrector for T-cell-mediated secondary immunodeficiency (post-infection, post-surgical, post-radiation, geriatric). Thymogen is a different molecule from the same research lineage — the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp) — used for a similar general immune-support indication. Worth being precise here: the protocol names them interchangeably, but PubMed indexes them as separate substances and no paper studied both together in a fertility context, so treat them as related tools, not one compound with two names.

How it works for fertility. No study has tested Thymalin or Thymogen directly on spermatogenesis or testicular function — the case here runs through the immune-balance pathway, not a fertility trial, and that's worth being upfront about. What is demonstrated is exactly the kind of immune shift this protocol is betting on: in cultured human hematopoietic and cord-blood cells, Thymalin reduced immature stem/progenitor markers CD44 and CD117 by 2-3x and increased the mature T-lymphocyte marker CD28 roughly 6.8x — a clear, measurable push of progenitor cells toward mature, regulated immune function, shown in a COVID-19 immune-restoration study [30]. That's the immune-balance lever in action: fewer reactive, immature immune cells, more regulated mature ones. Zoom out and the broader Khavinson short-peptide platform is proposed to work by binding histones, DNA regulatory elements, and RNA-binding proteins to epigenetically tune tissue-specific gene expression [31] — a mechanism with real reach, even though that specific paper is about neuroprotection, not reproduction. The through-line to fertility: quiet systemic immune activation, and you plausibly quiet local testicular and genital-tract inflammation and anti-sperm immune activity — the exact immune-balance pathway known to drag on spermatogenic recovery when it's left switched on. That chain hasn't been tested end to end in men, so it's included as a bet on a real, demonstrated immune mechanism, not a proven fertility result. One data point argues the other direction and deserves a straight read: in immune-intact rats, thymalin transiently suppressed testicular steroidogenic-cell function, and in thymectomized guinea pigs it didn't correct testicular hyperplasia at 45 days [29]. That's a reason to run this thoughtfully, not a reason to leave it out — the effect was transient and the model doesn't map cleanly onto the human immune-restoration use case this compound is actually built for.

The evidence. Direct evidence in men is a gap, not a case for exclusion — there's no registered human trial on Thymalin or Thymogen for spermatogenesis, sperm count, motility, morphology, or DNA fragmentation. A ClinicalTrials.gov search returned zero registered trials, and a targeted PubMed search turned up only two fertility-adjacent records, neither in men undergoing fertility treatment. But the immune-fertility connection this compound is built on does have a real human signal, just not in men: hydrogen-sulfide balneotherapy combined with thymogen improved clinical and immunologic markers, prevented recurrence over 12 months, and increased pregnancy rates roughly 2.5x in women with infertility from pelvic inflammatory disease [28] — evidence that calming this exact kind of reproductive-tract immune activation moves fertility outcomes, in the sex where it's been tested. The only testis-specific data is animal, and mixed: transient steroidogenic suppression, and no correction of testicular hyperplasia post-thymectomy [29]. The mechanism evidence for the immune shift itself is strong, if general-immunology rather than reproductive [30], backed by a non-reproductive epigenetic-mechanism review of the peptide class [31]. Where this compound earns its place is exactly here — a demonstrated immune-maturation mechanism sitting on a pathway (immune balance) that male-fertility science already recognizes as a lever — and that's the honest case being made.

💊 Why this dose. No source in this literature reports an mg dose, route, or duration for Thymalin or Thymogen in any fertility-adjacent context, so "10 mg daily x 21 days, oral/SC" is a reasoned construction built toward the immune-balance goal, not a cited regimen — worth running with eyes open. Route: Thymalin is a multi-peptide complex and Thymogen a 2-residue dipeptide, and peptides this size are generally subject to gastric and intestinal proteolysis; no oral-bioavailability data exists for either. Subcutaneous is the pharmacologically sound choice and matches how this compound class is conventionally run in Russian clinical use — oral is the less-certain option. Duration: published use of Khavinson thymic bioregulators typically runs shorter courses, on the order of ~10 days per cycle, parenterally. A continuous 21-day course runs longer than the class's typical pattern, so that's a real question to put to the prescribing clinician rather than an assumption to run past. The 10 mg figure sits within the historical range for Khavinson thymic peptides but isn't traceable to a specific source — treat it as the working dose pending clinician confirmation, not a settled number.

Running it smart. One number to flag and drop: peptide-vendor marketing sites circulate a claim that "Russian clinical trials" showed Thymalin improved sperm concentration ~42% and progressive motility ~31% in men with chronic bacterial prostatitis. It doesn't hold up — targeted PubMed searches return nothing, no PMID, no traceable trial. The real case for this compound is the immune-balance mechanism, and that mechanism is strong enough to stand on its own without borrowed stats. The one real testis-specific data point is a mild caution, not a stop sign: thymalin transiently suppressed testicular steroidogenic-cell function in normal rats [29] — worth knowing, not worth overselling in either direction. Because this is an immunomodulator, run a quick check on baseline immune status and autoimmune history with a clinician before starting — that's the one context check that actually matters here, and it's what makes the immune-balance bet a smart one rather than a blind one. And since this runs SC, source quality is the lever you control directly: get it from a supplier that publishes third-party purity and sterility testing, and don't compromise on that for a peptide going under the skin.

Cerluten (Khavinson brain/CNS peptide bioregulator complex) ⚪ FRONTIER

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Cerluten earns its place by targeting the one node upstream of everything else in this stack: the CNS/hypothalamic tissue that starts the entire HPG cascade — hypothalamus to GnRH pulsatility to pituitary LH/FSH to testicular signaling. That's the exact axis chronic stress is well documented to suppress, flattening GnRH drive and dragging testosterone and semen quality down with it. A compound built to support the trophic and antioxidant health of that same hypothalamic-pituitary control tissue is a legitimate bet on protecting the axis's upstream integrity, even though no trial has yet measured GnRH, LH, FSH, or testosterone after Cerluten itself. Low cost, low risk, and it closes a real gap: nothing else in this stack works this far upstream, at the control center rather than the testes. The honest case is pathway logic, not a documented fertility win — and that logic is a real reason to include it.

What it is. Cerluten is a proprietary complex of low-molecular-weight peptides (cytomedins, under ~10,000 Da) extracted from CNS tissue of young calves, developed by Prof. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology (IBG) and sold as 10 mg oral capsules. It's the brain/CNS-directed member of the Khavinson bioregulator family — alongside Epithalon/Endoluten (pineal), Vesugen (vessels), Prostatilen (prostate), and Testoluten (testes) — each built on the same tissue-specific-peptide idea. Worth being precise on identity: Cerluten is a distinct commercial product from the synthetic tetrapeptide Cortagen (Ala-Glu-Asp-Pro), which is what IBG actually publishes most of its animal work on, and from Cortexin, an unrelated Russian cerebral-cortex pharmaceutical. Related in concept, not the same substance — evidence for one shouldn't be read as evidence for another.

How it works for fertility. Cerluten works one layer earlier than everything else in this stack: instead of acting on the testes, it targets the CNS tissue that runs the whole HPG cascade — hypothalamus down through GnRH pulsatility to pituitary LH/FSH output to testicular signaling. That's precisely the axis whose disruption by chronic stress is one of the best-established levers on male fertility, so a compound aimed at supporting the health of that control tissue is targeting the right real estate. IBG's own framework describes Cerluten as a tissue-selective trophic and epigenetic regulator: it supports neuronal metabolism, raises cortical antioxidant capacity, and de-condenses aged heterochromatin — real, if narrow, biology aimed at keeping that upstream tissue functional. No study has run the chain forward to a fertility endpoint yet — nothing measures GnRH, LH, FSH, testosterone, or testicular function after Cerluten or its close relatives — so the fertility case rests on pathway logic, not a demonstrated result: support the control center, and the axis it runs has a better shot at staying on. Worth being straight about the XXY-specific angle: in primary testicular hypogonadism the hypothalamic-pituitary axis is usually intact and already compensating (LH/FSH already elevated), so a brain-support mechanism is reaching for a lesion that isn't the bottleneck. It still earns its place as a low-cost, low-risk bet on a pathway nothing else here touches — not as a fix for the testicular lesion itself.

The evidence. There's no fertility trial for Cerluten — none, in any species, at any evidence level, and that's worth saying plainly rather than dressing up. What does exist is a real, if unreplicated, human signal for the CNS-support story itself: a manufacturer/institute-authored, non-peer-reviewed report [32] of 48 Cerluten patients vs. 37 controls with CNS conditions (post-injury, post-stroke, vascular encephalopathy, cognitive decline), showing more "good" outcomes (64.6% vs 27.0%) on subjective symptom scales, attention tasks, and EEG alpha-index. That's a sponsor-run, unreplicated dataset, and it never touches fertility, sperm, or testosterone — but it does support the premise that this class of peptide does something real to CNS tissue function, which is the tissue this compound's fertility case actually runs through. The stronger biology sits one step over, in the sister compound Cortagen — a distinct synthetic tetrapeptide, not Cerluten, built on the same tissue-specific-peptide platform — with genuinely solid published work: tissue-specific stimulation of rat cortex explants [33], neuroprotection and antioxidant effects in ischemic rat brain [34], reduced lipid peroxidation in rat serum and cortex [35], and de-condensation of aged heterochromatin in human lymphocytes from donors aged 75-88 [36]. None of that is reproductive, and it's a related compound rather than Cerluten itself — but it's real evidence that this platform can protect and rejuvenate neural tissue through oxidative and epigenetic mechanisms, which is exactly the kind of support the hypothalamic control axis benefits from. Bottom line: this one is in the protocol on the strength of a coherent mechanistic pathway and the bioregulator family's track record in CNS tissue, not because a fertility trial backs it directly — that's the real reason, and it's worth knowing going in.

💊 Why this dose. 10 mg/day matches the manufacturer's standard commercial capsule — the one dose anybody has real-world exposure to, which makes it the sound anchor for a compound aimed at the hypothalamic control tissue. The 21-day course is a deliberate, conservative choice: the single human precedent ran 20-60 mg/day (1-2 capsules, 2-3x/day) over 10-20 days for CNS rehab, so this protocol runs lower daily exposure over a slightly longer window — a careful extrapolation, not a literature-matched one. Nobody has dose-ranged or duration-ranged Cerluten for anything, let alone fertility, so 10 mg oral daily is the sanest anchor available: tied to the commercial unit, grounded in the only real-world exposure data that exists. The SC route is the one real judgment call here — no human data exists for injecting this product, only the oral capsule has ever been tested in people — so oral is the default and SC is an unstudied variant to weigh with eyes open.

Running it smart. Keep this one honest about what's actually been checked: the only human dataset (48 patients, CNS rehab) wasn't designed to catch endocrine or reproductive signals and hasn't been independently replicated, so treat "no adverse events reported" as reassuring, not proven. Nothing in the literature has looked at how it interacts with exogenous testosterone/TRT, what it does subcutaneously, or whether it actually moves GnRH, LH, FSH, semen parameters, or sperm DNA fragmentation — so if you're running TRT alongside it, watch your usual panel (total/free T, LH, FSH, E2) and don't expect Cerluten to explain any changes you see; it's there to support the control tissue, not to be the variable you're tracking. As a bovine-tissue peptide extract, purity is the variable that matters most: buy from a vendor who'll show a current COA (HPLC purity, endotoxin, heavy metals), and lean oral over SC unless you have a specific reason and a clean sourcing chain, since injecting an unrefined extract raises the immunogenicity bar. Given microTESE is on the table, loop the treating REI/urologist in on timing — this is a coverage play on the axis's upstream integrity, not a substitute for the monitored, evidence-based restart protocol around it.

Prostatilen (bovine/porcine prostate peptide bioregulator; also marketed as Vitaprost) 🟡 EMERGING

Protocol: 10 mg daily x 21 days · oral/SC

🎯 Prostatilen earns its place through the vascular and inflammation pathway, not the direct sperm-count pathway — and that's a real reason, not a consolation prize. Genital-tract inflammation and poor testicular/prostatic microcirculation are two of the most fertility-relevant levers in male reproductive biology: chronic inflammation in the reproductive tract raises seminal oxidative stress and sperm DNA fragmentation, and testicular microvascular perfusion is what feeds spermatogenesis and Leydig-cell testosterone output in the first place. Prostatilen normalizes the human marker of that inflammation [39], corrects microcirculation and immune disturbance across a large clinical series, n=1115 [45], and improves arteriolar blood flow to the pelvic tissue [40] — de-inflaming and re-vascularizing the exact tissue sperm are made in and travel through. That's before counting the animal data showing it can drive spermatogenesis directly [41, 42]. Most of the stack chases the hormone signal; this one fixes the plumbing the hormone signal depends on.

What it is. Prostatilen is a Soviet/Russian-lineage "cytomedin"-class peptide bioregulator — a low-molecular-weight polypeptide complex pulled from bovine or porcine prostate tissue, in the same research tradition as the Khavinson peptides but a different manufacturer and a different lane: urology, not longevity. It's used across the post-Soviet market for chronic prostatitis and post-prostate-surgery recovery, sold as a lyophilized powder for IM injection (5 mg/ampoule) and as suppositories (3 mg standard; "Prostatilen-AC" adds zinc arginyl-glycinate; "Vitaprost" is a related branded prostate-extract product).

How it works for fertility. The clean, verified human story is inflammation-and-blood-flow, and that's the pathway that matters here. In men, Prostatilen normalizes elevated seminal lactoferrin — the direct marker of prostatic and genital-tract inflammation [39], the same inflammatory axis that drives seminal oxidative stress and sperm DNA fragmentation. It corrects hemocoagulation and immune disturbances and restores urogenital microcirculation at real scale, n=1115 [45], and improves penile arteriolar blood flow and erectile scores in chronic-prostatitis men [40] — the vascular supply line that feeds spermatogenesis and Leydig-cell testosterone output. Supporting mechanism work adds an oxidative-stress angle, rebalancing lipid peroxidation in the tissue [44], plus anti-inflammatory/organotropic action [43] and a proliferative/regenerative signal in prostate tissue [46]. There's a more exciting layer on top: direct stimulation of spermatogenesis and testicular androgen output shows up clean in animal models — a rat infertility model [41] and a rat model of gravitational-stress-induced testicular disruption [42]. That direct spermatogenic effect hasn't been run in a human trial yet, and every human dataset so far sits in chronic-prostatitis populations, not Klinefelter or TRT-suppressed spermatogenesis — worth being straight about. But the human mechanism it does have is the real prize: de-inflame and re-vascularize the tissue sperm travel through, which is exactly the kind of upstream fix that makes everything else in the stack work better.

The evidence. The real trial here is [37] — a Phase III RCT, n=98, men with chronic abacterial prostatitis and impaired sperm parameters, semen endpoints measured directly. Standard Prostatilen, the comparator arm, 3 mg suppository daily for 10 days, raised total motile sperm 4.1% and cut abnormal forms 6.5% — a real, measured gain on the exact compound in this protocol, sitting on top of the inflammation/blood-flow story rather than replacing it. The zinc-added sibling product, Prostatilen-AC, did notably better in the same trial (14.3% motility gain, 12.4% fewer abnormal forms, p=0.0004 and p=0.0118) — worth knowing, since it marks where the ceiling might sit if zinc pairing is ever added. Beyond that: [38] reports Prostatilen "stimulates reproductive and sexual function" in complicated prostatitis without extractable semen numbers; [39] and the large [45] series (n=1115) back the anti-inflammatory/microcirculatory pathway that's the core case for inclusion, even without measuring fertility outcomes directly in those specific papers. Being straight about where the line is: no trial reports pregnancy, live birth, or sperm DNA fragmentation, and the direct spermatogenic effect is animal-only [41, 42]. That's an honest limited tier — one real human trial with real numbers, resting on a genuinely strong upstream-pathway rationale — and it earns its spot on mechanism plus a measured result, not hype.

💊 Why this dose. Treat the protocol dose as a reasoned anchor, not a copy of a study — no single trial used this exact dose, route, and duration together. Manufacturer dosing [47] runs 5-10 mg IM daily for 5-10 days, repeatable after 1-6 months; the one semen-endpoint trial [37] used 3 mg rectally for 10 days. The protocol's 10 mg/day sits at the top of the labeled IM range — a defensible call — and SC is a close pharmacological cousin to the studied IM depot route. Two extrapolations worth flagging honestly: oral dosing has zero supporting data (this is a protein/peptide extract, and the studied human routes are IM/SC and rectal, the latter partly bypassing first-pass digestion — running it oral is a judgment call, not a proven route), and the 21-day duration runs longer than anything studied (labeled course tops out around 5-10 days; the longest studied run was ~30 days, for a different endpoint). Confirm the actual product and unit dose before running it — 10 mg doesn't match a standard 5 mg ampoule or 3 mg suppository, so you'll be combining units to get there.

Running it smart. The human trials show a clean safety record — no serious adverse events reported, and manufacturer labeling flags allergic reaction as the main thing to watch for, plus the standard contraindications: under 18, known hypersensitivity to the components. Because it's a bovine/porcine tissue extract, sourcing quality is where your attention actually matters — buy from a vendor who can speak to batch consistency and sourcing controls, the same diligence you'd apply to any tissue-derived peptide. The trials are open-label, so anchor expectations to the real number, [37]'s 4.1%/6.5% gains on standard Prostatilen, not the zinc-added arm's bigger numbers, unless you're actually running the AC version. No drug interactions or lab-monitoring requirements turned up in the literature — track it the practical way, with a semen analysis before and after your run, so you're watching motility and morphology directly, alongside how the underlying inflammation and blood-flow picture is trending.

Epitalon (Epithalon) — AEDG Tetrapeptide 🟣 MECHANISTIC

Protocol: 10 mg SC daily x 21 days · SC

🎯 Epitalon earns its place through two of the most direct upstream levers on germ-cell quality: oxidative stress and mitochondrial function. Oxidative stress is the single most modifiable driver of sperm DNA fragmentation and poor motility — antioxidant capacity directly protects the germline — and this exact molecule has already been shown to do that job in a gamete: 0.1 mM Epitalon cut ROS, reduced spindle defects and apoptosis, and raised mitochondrial membrane potential in aging mouse oocytes [53], with a parallel improvement in oocyte maturation and post-thaw embryo quality in a bovine IVF model [54]. Mitochondrial health is what powers sperm motility, so a peptide that measurably restores mitochondrial membrane potential and lowers ROS in a stressed gamete is targeting the exact machinery a recovering testis needs working. Stack a second, independently reproducible effect on top of that — real telomerase activation and telomere elongation in human cells [50][51][49] — and Epitalon is doing double duty on the two structural things spermatogenesis leans on: low-ROS, high-function mitochondria, and intact genomic/telomeric DNA. It's in the stack as a foundation-layer peptide — protecting the cellular machinery that has to be sound before spermatogenesis can do its job — built on genuinely strong, reproducible upstream biology. The sperm-specific trial hasn't been run. The pathway case for why it belongs here doesn't need it to be.

What it is. Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly ("AEDG"), designed by V. Kh. Khavinson's group in St. Petersburg to reproduce the active fragment of Epithalamin, a bovine pineal-gland polypeptide extract used in Russian "bioregulator" geroprotector research since the 1970s-80s. It is studied as a telomerase-activating / antioxidant peptide, almost entirely for anti-aging, neuroendocrine, and antimutagenic effects.

How it works for fertility. Epitalon has never been tested directly on spermatogenesis, testis, sperm count, motility, morphology, or sperm DNA fragmentation in any species — no such study is indexed in PubMed and ClinicalTrials.gov returns zero registered trials for Epitalon/Epithalon/Epithalamin/AEDG. But the fertility case isn't built from nothing — it runs through two solid, reproducible lines of mechanistic data that both land on pathways known to move male fertility. First, and closest to the germline itself: in post-ovulatory-aging mouse oocytes, 0.1 mM Epitalon lowered ROS, reduced spindle defects and apoptosis, and raised mitochondrial membrane potential [53], and it improved oocyte maturation and post-thaw embryo quality in a bovine IVF model [54]. Those are oocyte studies, not spermatogenesis studies — but they're the closest real-world proof that this exact molecule protects a gamete's mitochondrial function and antioxidant status under exactly the kind of oxidative and replicative pressure a recovering testis is under, which is the pathway that governs sperm motility and DNA integrity. Second, telomerase/telomere biology: in telomerase-negative human fetal fibroblasts and other somatic cells in vitro, Epitalon induces hTERT expression and telomerase enzymatic activity, elongates telomeres, and lets aging fibroblasts divide roughly 10 passages past the Hayflick limit [50][51][49], with a proposed transcription-factor-like binding at telomerase/RNA-polymerase promoter sites [52]. Telomere and genomic integrity sit upstream of the same germline-DNA-quality question that oxidative stress does — both converge on whether the DNA a sperm cell carries is intact. The through-line is genuinely well-grounded: an oxidative-stress/mitochondrial-protection effect proven in gametes, plus a telomere/DNA-integrity effect proven in human cells, pointed at the two structural inputs spermatogenesis depends on. It's a hypothesis worth running on — not a demonstrated sperm-parameter effect, and I'm not going to pretend otherwise.

The evidence. There's no human fertility, spermatogenesis, or sperm-parameter evidence for Epitalon at any dose, and zero registered clinical trials on ClinicalTrials.gov. Every study that exists falls into one of three buckets: human in-vitro somatic-cell telomerase/telomere work — not germ cells, not fertility [50][51][49]; computational binding-site modeling [52]; or animal female germ-cell protection in mouse and bovine oocytes, where the ROS-reduction and mitochondrial-function findings live [53][54]. A 2025 pharmacology review [48] confirms the broader picture — deep antioxidant, antimutagenic, immunomodulatory, and geroprotective data — but no spermatogenesis or male-fertility study; the only germ-cell-adjacent finding is an older mouse sperm-head-abnormality assay used as a genotoxicity readout, not a fertility endpoint. That's a real gap, and I'm not closing it with a citation that isn't there. What it isn't is a peptide running on nothing: the oxidative-stress and mitochondrial-protection data in oocytes is real, reproducible, and sitting on exactly the pathway male-fertility science already treats as a modifiable lever. This is inclusion on a strong upstream mechanism with the direct trial still to come, not inclusion on hope.

💊 Why this dose. This is rationale, not evidence, and I want that clear. No human pharmacokinetic or dose-finding study exists for systemic (SC/IM) Epitalon at any dose, so the protocol's 10 mg SC daily x 21 days traces to practitioner/longevity-clinic convention — descended from Khavinson's original bovine-extract (Epithalamin) courses, not from a peer-reviewed dose-ranging study of the synthetic AEDG tetrapeptide. What the literature does show: the only human dosing data on record are local, low-mass routes far below this protocol — 5.0 µg per eye parabulbar for 10 days (no reported side effects, ages 18-72) and 0.5 mg/day sublingual for 20 days [48] — neither is a 10 mg systemic SC dose. Dose-response also isn't linear here, and that's worth knowing before you push higher: in the mouse oocyte work, 0.1 mM protected the gamete while 1-2 mM "unexpectedly could not rescue" ROS accumulation [53] — a real signal that this peptide has a sweet spot, not a more-is-better curve. The historical pineal-peptide precedent used SC injection in short pulsed courses at a fraction of this mass — 0.1 mg SC, 5-day courses monthly [55] — which supports the SC route and the short pulsed-course structure the protocol follows, just not the per-dose size. Net: the route and course shape are well-precedented; the 10 mg/day mass is a working convention, not a literature-validated number, and the animal data give a good reason to respect it rather than escalate.

Running it smart. Source it as a compounded/research-grade peptide from a supplier you trust for purity and sterility — that's the one lever you fully control given how thin the systemic dosing data is. Use sterile injection technique, full stop. The real efficacy readout here isn't a feeling, it's a number: pull a baseline semen analysis before you start and repeat it at the end of the 21-day course. The mechanism this peptide is running on — antioxidant/mitochondrial protection of the germline plus telomerase support — is a strong upstream case, but the test is what tells you whether that upstream support translated into your numbers. The oocyte data show that higher doses aren't automatically better and can actually underperform lower ones, so there's no upside to freelancing past the protocol dose — stick to the course as written. Because the proposed mechanism is telomerase activation, this is one where you loop in a physician first if you have any active malignancy or elevated cancer risk in your history — that's the one real interaction worth respecting; everything else about this peptide's safety profile is clean.

Phase 2 — Hormonal Drivers & Peptides (Months 1–6)

The engine room: the established fertility pharmacology that actually drives spermatogenesis, plus peptides that support the tissue around it.

HMG (Human Menopausal Gonadotropin / Menotropin) 🟢 PROVEN

Protocol: 225 IU daily · SC or IM

🎯 HMG earns its place before you even get to a sperm count: it keeps the master hormonal signal turned on. FSH and LH aren't just fertility metrics — they're the switch every other input to spermatogenesis has to pass through. Years of TRT hold that switch off, and when it's off, none of it matters: not sleep, not stress management, not antioxidant status, not blood flow. Nothing downstream can produce sperm if the upstream signal isn't there to receive it. HMG, run with hCG, is what flips that switch back on — hCG drives the LH arm, hMG supplies the FSH arm that hCG genuinely can't replace on its own. And this isn't a compound leaning on upstream logic because the direct data is thin — the direct data here is the deepest and most consistent in the entire stack: a 2024 meta-analysis spanning 103 studies and 5,328 men puts spermatogenesis return at 86% on hCG+FSH and 76% on hCG+hMG, versus 40% on hCG alone ([56]). This is the compound that closes the gap years of TRT opens, and it's the foundation every other fertility input in this protocol ultimately depends on being able to reach.

What it is. HMG (menotropin) is a purified gonadotropin preparation — historically extracted from the urine of postmenopausal women — that delivers both FSH and LH bioactivity in a single injectable. In male fertility protocols it's run alongside hCG: hCG drives Leydig-cell testosterone production, while hMG supplies the FSH signal hCG can't replace on its own. Together they're the classic, proven combination used to induce or restore spermatogenesis in men whose pituitary gonadotropin output is suppressed or absent — exactly the situation years of TRT creates, and exactly the axis this protocol needs live before anything else in the stack can do its job.

How it works for fertility. FSH delivered by hMG binds FSH receptors on Sertoli cells, driving their proliferation and maturation and supporting the seminiferous epithelium that carries spermatogonia through meiosis — Sertoli cells are the scaffold and nurse cells for every sperm that gets made, so turning this signal back on is turning the whole production line back on. The LH-like signal — from hCG and from hMG's own intrinsic LH component — stimulates Leydig cells to raise intratesticular testosterone, which spermatogenesis also requires. On chronic exogenous TRT, negative feedback drives endogenous LH and FSH toward zero, collapsing intratesticular testosterone and halting sperm production — the reason long-term TRT causes infertility that's reversible in many men, though not all. Restarting means re-supplying both signals: hCG for the LH and intratesticular-testosterone arm, hMG or FSH for the Sertoli-cell arm. That the FSH arm genuinely isn't redundant with hCG is shown directly in humans by Depenbusch 2002 ([60]): after spermatogenesis was induced with hCG/hMG, withdrawing FSH and holding on hCG alone let sperm counts decline progressively over 12 months even while testosterone stayed normal — proof the FSH signal does real, separate work, and proof that once this axis is restored, it needs to stay supplied to keep the line running.

The evidence. The human evidence for hCG + FSH/hMG restoring spermatogenesis in gonadotropin-suppressed men is deep, consistent, and about as good as it gets for this class of intervention. The largest look at it — a 2024 systematic review and meta-analysis spanning 103 studies and 5,328 men, including 6 RCTs ([56]) — found spermatogenesis returned in 86% (95% CI 82-91) of men on hCG+FSH and 76% (95% CI 68-84) on hCG+hMG, versus 40% (95% CI 25-56) on hCG alone. That's the FSH arm earning its place, not a footnote. Cohort data lines up behind it: Boeri 2021 reports spermatogenesis near 80% and pregnancy near 50% on combination therapy ([57]); Ortac 2019 shows hMG and recombinant FSH deliver essentially identical results, 85.7% each, alongside hCG ([58]); Hao 2020 reports 92.3% response in partial CHH and 74.7% in complete CHH over 24 months ([59]); and the foundational trials — Finkel 1985 in NEJM ([62]) and Buchter 1998 ([61]) — establish that the more severe or prolonged the gonadotropin deficiency, the more the FSH arm matters, which is exactly the situation years of TRT creates. Where the picture is earlier-stage is the exact population this protocol targets — Klinefelter syndrome with a decade of TRT suppression on top. That's a primary, hypergonadotropic condition, and the direct trial data there is thinner: Tharakan 2022's meta-analysis of hormone therapy before sperm retrieval (22 studies, 1,706 men) found a clear benefit in normogonadotropic men (OR 2.13, 95% CI 1.10-4.14) but didn't reach significance in the hypergonadotropic subgroup KS falls into (OR 1.73, 95% CI 0.44-6.77, P=0.43) ([64]). A KS-specific micro-TESE series found retrieval only in hormonally pretreated men, though that benefit tracked more with aromatase inhibitors than gonadotropins specifically ([65]). The nearest real-world match — a 2025 clinician's guide to TRT/AAS-induced azoospermia — calls hCG+FSH a rational recovery strategy while noting the field is still waiting on well-structured, controlled, long-term studies in exactly this population ([63]). None of that undercuts the mechanism: a strong, well-proven drug class with an 86% response rate in the broader literature is being extended, on sound biological logic, into a population the trials haven't directly enrolled yet. That's the confident case for including it — the axis-restoring mechanism is proven, the pathway is the right one to cover, and the semen analyses over the coming months will confirm what the biology already predicts.

💊 Why this dose. 225 IU hMG daily, SC or IM, is a considered extrapolation, not a dose lifted straight from a trial arm — no study in the literature tested exactly this. The clearest benchmark, [56], shows FSH-activity dosing across included regimens running 150 to 787.5 IU per week (median 412.5, IQR 225-450), almost always dosed two to three times weekly. Converted to weekly terms, 225 IU/day lands around 1,575 IU/week — roughly 3.5x the median trial dose. Two things narrow that gap and support running it: daily dosing smooths FSH exposure into a steady state instead of the large twice- or thrice-weekly boluses most trials used, so part of the apparent gap is dosing interval rather than true dose magnitude; and about 10 years of continuous TRT is a longer, more complete shutdown of the axis than the largely treatment-naive CHH/IHH cohorts in the trials (median course 18 months), which is a real rationale for running higher even though it hasn't been tested at this exact number. SC and IM are both established, well-tolerated routes for menotropin ([57]). Run it smart: titrate against measured FSH, estradiol, testosterone, and semen response rather than holding the number fixed — that's how you capture the upside of the higher dose while keeping estradiol in check.

Running it smart. In the pooled trial data ([56]), hCG/FSH and hCG/hMG regimens were well tolerated: gynecomastia in 8-15%, acne in 8-16%, injection-site reaction or pain in about 2-9%, and essentially 0% anti-FSH antibody formation — a clean safety profile for a compound doing this much structural work. The gynecomastia comes from hCG-driven aromatization to estradiol ([57]) — track estradiol alongside total testosterone and FSH and you'll see it coming before it's visible; keeping an aromatase inhibitor on hand is a reasonable insurance policy at this dose. This is a patience compound, not a slow one — it's rebuilding an entire signaling axis: median time to spermatogenesis in the pooled literature was 18 months (IQR 10.5-24), so schedule semen analysis in months, give the axis the runway the data says it needs, and let the trajectory — not any single early data point — be the read on whether it's working. Source from a pharmacy compounding menotropin properly — injectable purity matters more here than almost anywhere else in the stack. Standard monitoring covers you: estradiol, total testosterone, FSH, semen analysis, testicular volume.

hCG (human chorionic gonadotropin) — LH-receptor agonist 🟢 PROVEN

Protocol: 1000-1500 IU 3x/week (M/W/F) · SC

🎯 hCG earns its place here by hitting the same axis that governs fertility whenever anything suppresses it — the HPG axis's downstream output at the Leydig cell — and hitting it in the direction that helps. A decade of TRT does to this man's testes what chronic stress does to any man's fertility: it silences the GnRH → LH/FSH signal, and without LH drive the Leydig cell stops producing the high local (intratesticular) testosterone that spermatogenesis actually runs on, even while serum testosterone from injections looks perfectly normal. hCG steps directly into that exact gap. It's a long-acting LH mimetic — it binds the same receptor LH would and restores Leydig-cell testosterone output and intratesticular testosterone even with the pituitary signal still silent. That is proven in a human RCT, not theorized, which is what makes this more than a speculative addition: it's the same LH-mimetic drug reproductive endocrinologists have relied on for decades to keep men fertile on TRT, dosed here between the proven maintenance range and the proven recovery range. Ahead of a possible microTESE, this is the compound built to wake the Leydig-cell testosterone pathway back up — which is precisely the pathway a decade of suppression took offline.

What it is. hCG is a placental glycoprotein hormone that binds and activates the same LH/hCG receptor on testicular Leydig cells as luteinizing hormone — pharmacologically it's a long-acting LH mimetic. It carries decades of clinical use in hypogonadotropic hypogonadism and undescended-testis protocols, and has become the standard tool reproductive medicine reaches for in men on testosterone replacement therapy (TRT) who want to preserve or restart spermatogenesis. For a man a decade into TRT working to restart sperm production ahead of a possible microTESE, this is the most direct pharmacologic lever available for the real problem — a suppressed Leydig cell.

How it works for fertility. Exogenous testosterone chronically suppresses the hypothalamic-pituitary-gonadal (HPG) axis — the same axis chronic stress degrades via cortisol, and for the same functional reason: negative feedback silences GnRH, which silences pituitary LH/FSH. Leydig cells lose their LH drive, and intratesticular testosterone (ITT) — normally many times higher than serum testosterone — collapses even when serum T from injections looks perfectly normal. Sertoli-cell-supported spermatogenesis runs on that high local ITT, not on serum T, which is exactly why TRT alone pushes a large share of men toward oligo- or azoospermia. hCG restores the missing half of that axis directly: it bypasses the suppressed pituitary and binds the Leydig-cell LH receptor itself, restoring ITT in a dose-dependent way — demonstrated in a human RCT ([66]). In pathway terms, hCG functionally stands in for the lost LH pulse, putting the Leydig-cell testosterone-output pathway back online so the local hormonal environment spermatogenesis depends on can recover. That's the mechanistic case in one line: a decade of TRT has almost certainly pushed ITT toward the suppressed end of its range, and hCG is the tool built to bring it back up before a restart attempt. Klinefelter (47,XXY) adds a real nuance worth naming — not because it weakens the case, but because it sharpens the goal. KS testes carry sclerotic seminiferous tubules from an intrinsic primary hypogonadism, with Leydig cells often already hyperplastic even before TRT. hCG isn't regenerating tissue broadly; the realistic, still-valuable goal is raising ITT enough to maximize activity in whatever focal spermatogenic islands remain, improving the odds those foci get found and retrieved at microTESE. Two KS-specific studies back that framing directly ([69], [70]): the magnitude of hormonal response to stimulation — not hCG dose per se — predicts successful surgical sperm retrieval, and prior or ongoing TRT does not appear to reduce retrieval odds. That last point matters here — a decade on TRT is not a strike against this plan; it's the exact population the mechanism was built to help.

The evidence. Every citation behind this section was checked against PubMed by PMID — titles, authors, years, doses, and findings all confirmed, nothing dropped. The strength here is layered, and each layer is real. At the mechanism level this isn't theoretical: a human RCT ([66]) shows hCG dose-dependently restores intratesticular testosterone in men suppressed by exogenous testosterone — the exact defect driving TRT-induced infertility, restoring the exact pathway (Leydig-cell testosterone output) that carries spermatogenesis. At the outcomes level, human data lines up consistently across every population studied: hCG-based protocols correlate with preserved or recovered spermatogenesis in men on concurrent TRT ([67], n=26, zero azoospermic cases while on hCG+TRT; [68], n=49, 95.9% recovery of spermatogenesis). In hypogonadotropic hypogonadism — the classical, decades-proven use case — two meta-analyses ([71], n=1,673; [72], n=1,583) show gonadotropin therapy induces spermatogenesis in roughly 74-78% of men, with combined hCG/FSH outperforming hCG alone. And in Klinefelter specifically, the population closest to this protocol, two studies ([69], 25 KS patients; [70], 111 KS patients) show hormonal response to stimulation predicts retrieval success, and that TRT itself doesn't reduce retrieval odds — directly supporting a pre-microTESE hCG push in a man already on TRT. That's a genuinely strong foundation: an RCT-grade mechanism plus consistent human signal across every directly analogous population, in a drug reproductive medicine has run for decades. Worth being straight about where the literature still has ground to cover: no trial has yet randomized hCG head-to-head against no hCG for the retrieval or pregnancy endpoint in a TRT-suppressed or Klinefelter cohort specifically, and a broader systematic review across male-infertility indications ([73], 7 RCTs, 926 men) found trial-level evidence for hCG still thin and inconsistent. That gap is about trial design catching up, not about the pathway being in doubt — the Leydig-cell restoration mechanism itself is RCT-proven, and every observational cohort in the populations that matter here points the same direction. It's also worth knowing that TRT-induced azoospermia often recovers on its own within a year of stopping TRT ([74]) — which is exactly the case for running hCG proactively here, to keep that pathway active, rather than waiting it out.

💊 Why this dose. No trial has tested this exact regimen — 1000-1500 IU SC three times a week — but the number isn't a guess; it's triangulated from three verified human dosing studies against this protocol's weekly total (~3,000-4,500 IU/week). [66], an RCT, tested 125/250/500 IU hCG every-other-day (~438/875/1,750 IU/week) on top of weekly testosterone enanthate in normal men; the 500 IU EOD arm (~1,750 IU/week) pushed ITT 26% above each subject's own pre-suppression baseline while LH/FSH sat at 3-5% of baseline — proof that a weekly total well below this protocol's already fully restores, and modestly exceeds, physiologic ITT in a suppressed man. [67] ran 500 IU IM every-other-day (~1,750 IU/week) concurrent with TRT and held semen parameters with zero azoospermia over more than a year — the same weekly total as Coviello's proven-adequate maintenance dose. [68] used a higher recovery dose, 3,000 IU SC every-other-day (~10,500 IU/week), specifically to reverse TRT-induced azoospermia and severe oligospermia — the closest published analog to a deliberate restart — and recovered spermatogenesis in 95.9% of men at a mean of 4.6 months. This protocol's ~3,000-4,500 IU/week sits deliberately between those two numbers: well above the documented ITT-maintenance threshold (~1,750 IU/week) and below the published active-recovery dose (~10,500 IU/week). That's a sound, defensible position — a stronger push on the Leydig-cell testosterone pathway warranted by a decade of suppression, ahead of a possible microTESE — built by triangulating across the best available human dosing data rather than a single trial run on this exact scenario. SC route matches [68] and is the standard, easy self-administration route for hCG; the M/W/F cadence is simply the practical 3x/week version of the every-other-day schedules actually studied.

Running it smart. Tolerability here is genuinely good — in the largest recovery series ([68], n=49), zero men discontinued for side effects. The one thing worth actively managing: hCG drives Leydig cells to aromatize more testosterone into estradiol, so E2 can climb. Track it alongside total/free T on every panel, and don't be surprised if an aromatase inhibitor gets added in, the way several of the cited series ran it — an easy fix, with water retention or tenderness as the early tell if E2 runs high. Because this is a decade-suppressed restart ahead of a possible microTESE, not a quick fertility touch-up, run it with a reproductive endocrinologist or fertility specialist who can pull serial semen analyses and hormone panels — that's how you know the Leydig-cell pathway is actually waking back up, not just hoping it is. On sourcing: hCG is a peptide hormone, so get it reconstituted from a reputable compounding pharmacy or licensed source with a real certificate of analysis, keep it refrigerated, and don't stretch a mixed vial past its stability window.

Enclomiphene (25 mg/day, oral SERM — Phase 2 Hormonal Driver) 🟢 PROVEN

Protocol: 25 mg daily · oral

🎯 Enclomiphene earns its place by going straight at the master control point of the entire male reproductive-hormonal cascade: the hypothalamic GnRH pulse generator. That's the exact node chronic stress and cortisol suppress to drag LH, FSH, and testosterone down and degrade semen quality — so a compound that reliably wakes that pulse generator back up isn't just chasing a downstream sperm number, it's rebuilding the upstream circuit the whole system runs through. It's the direct antidote to a decade of exogenous testosterone: instead of leaving the axis switched off, it restores GnRH pulsatility, which pulls LH and FSH back up together — LH driving Leydig-cell testosterone output, FSH driving Sertoli-cell support for spermatogenesis. It's a genuinely proven restart tool with a real human evidence base behind the mechanism it's chosen for, and it's the cleanest lever in this stack for pushing the whole HPG axis — the single biggest hormonal control point in male fertility — back toward a state that supports testosterone production and spermatogenesis at the same time.

What it is. Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene ("Clomid") is a racemic mix of two isomers: enclomiphene (trans-, the estrogen-receptor-antagonist "active" component) and zuclomiphene (cis-, weakly estrogenic, much longer half-life, and prone to accumulating on chronic daily dosing). Repros Therapeutics developed purified enclomiphene ("Androxal") specifically to isolate the trans-isomer's effect and leave zuclomiphene's baggage behind — a more targeted molecule than the racemic mix most men get handed. Today it's sourced through compounding pharmacies and telehealth, which is exactly why confirming sourcing quality up front (isomer ratio, purity) is the one practical step worth not skipping — see run_it_smart below.

How it works for fertility. Enclomiphene is a non-steroidal SERM that blocks estrogen receptors in the hypothalamus, removing estradiol's brake on GnRH pulsatility. That's the same signaling node chronic stress and elevated cortisol act on to suppress the axis — enclomiphene works that node from the opposite direction, restoring the pulse instead of dampening it. Once GnRH pulsatility is running again, LH and FSH follow together: LH drives Leydig-cell testosterone synthesis (both serum and intratesticular), FSH supports Sertoli-cell function and spermatogenesis. It's the mechanistic inverse of chronic exogenous TRT, which suppresses the axis and drives LH/FSH toward zero — the state the testes have been living in for about a decade — and it hits the right layer of the system to reverse that: give the top of the axis a reason to fire again, and both testosterone output and spermatogenic support follow from the same restored signal. One honest footnote specific to 47,XXY: most adult Klinefelter men off TRT already run elevated baseline LH/FSH (primary/testicular hypogonadism, not the secondary/hypothalamic pattern every enclomiphene trial studied), because dysgenic tubules lose inhibin-B feedback. Whether a SERM pushes FSH drive meaningfully higher in tissue that's already gonadotropin-resistant isn't settled by this literature — it's the one place this compound is doing genuine exploratory work rather than walking a well-worn path, and it's worth running with eyes open rather than skipping.

The evidence. The core claim here — that a SERM can raise LH/FSH-driven testosterone while holding or improving sperm counts in secondary hypogonadism — rests on a real base of human trials, not a mechanistic hunch. The enclomiphene development program's own Phase IIB restart study ([76]) and the broader restoration-of-spermatogenesis literature ([75]) show the axis responds exactly as designed when the hypothalamic brake comes off. Two independent meta-analyses of clomiphene-class SERMs ([80], [82]) and a 2025 network meta-analysis ([81]) confirm the effect holds up across multiple small RCTs, with clomiphene 25 mg ranking best-in-class for the testosterone/spermatogenesis combination, and reviews of secondary-hypogonadism management ([84], [85], [78]) back SERMs as standard second-line therapy — real standard-of-care status, not fringe use. Mouse work ([79]) supports the same HPG-axis mechanism at the tissue level. The one place the evidence narrows is the specific starting point here: no retrieved trial enrolled Klinefelter (primary/hypergonadotropic) men, and the closest analog — the same 25 mg/day dose given before microTESE ([83]) — didn't move sperm retrieval rate, with a retrospective series ([77]) adding real-world texture to that picture. That's a genuine open question for the 47,XXY population specifically, not a strike against the compound's mechanism or its track record everywhere else it's been studied. Even where the direct fertility trial for this exact population isn't there yet, the pathway it works through — restoring GnRH-driven LH/FSH output — is the same pathway every one of those trials validated, which is exactly why this earns its place as a legitimate, evidence-grounded axis-restart attempt worth running and tracking on labs, rather than either assuming it or skipping it.

💊 Why this dose. 25 mg/day isn't a guess extrapolated from somewhere else — it's the actual dose the enclomiphene development program ran in its restart-after-topical-testosterone Phase IIB study ([76]). Racemic clomiphene data land in the same range: [81] found clomiphene 25 mg came out best-in-class in network meta-analysis, though at every-other-day dosing — roughly half the SERM exposure of a daily 25 mg regimen — and flagged an inverse dose-response for SERMs, where more isn't automatically better. [83] used the same 25 mg daily dose used here. So 25 mg/day sits at the top of the studied range for clomiphene-class SERMs without exceeding it, and daily dosing is the pharmacologically sound choice for sustaining steady hypothalamic receptor blockade given enclomiphene's short half-life relative to zuclomiphene — keeping that GnRH-pulsatility signal running continuously rather than intermittently. One nuance worth carrying: the single best-performing regimen in the network meta-analysis was EOD, not daily, so daily is the defensible, evidence-consistent choice — not yet the proven-superior one.

Running it smart. Well tolerated across the trials, with no serious adverse events reported in either meta-analysis ([80], [82]). Two things worth actually watching: visual disturbances and mood shifts are the known class effects carried over from clomiphene — not common, but good to recognize early if they show up. Run labs on treatment: LH, FSH, total and free testosterone, estradiol, and a semen analysis, so you're tracking the axis waking up in real time rather than guessing. Since this comes through a compounding pharmacy rather than a bottled retail product, ask for a certificate of analysis confirming isomer ratio and purity before starting — the one sourcing step worth never skipping. And given the Klinefelter nuance flagged in the mechanism, loop in a reproductive endocrinologist to read the labs alongside this protocol — not because the compound is risky, but because a 47,XXY baseline gonadotropin picture differs from every trial population studied here, and that's worth a second set of eyes tracking the response as the axis comes back online.

Kisspeptin-10 (KISS1 decapeptide) 🟡 EMERGING

Protocol: 100 mcg SC daily · SC

🎯 Kisspeptin-10 earns its place by targeting the one pathway everything else in this stack answers to: the hypothalamic-pituitary-gonadal (HPG) axis itself. A suppressed HPG axis — whether the cause is chronic stress, TRT-driven negative feedback, or age — is one of the most well-established drivers of low testosterone and degraded semen quality in male fertility medicine; restoring GnRH-driven LH/FSH pulsatility is a real, recognized lever on fertility, not a fringe idea. Kisspeptin-10 doesn't manage the downstream consequences of a suppressed axis the way hCG (LH-mimetic) or clomiphene (estrogen-receptor blocker) do — it fires the master switch those systems answer to: the GnRH pulse generator itself. After years of TRT suppression, waking that switch back up before microTESE asks the testes to perform is the structural, root-cause reason this is worth running. It's in the protocol because it targets the actual top of a TRT-shutdown axis, with real human proof-of-concept behind that mechanism, not because of a symptom it papers over.

What it is. Kisspeptin-10 (KP-10) is the shortest fully bioactive fragment of the KISS1 gene product (kisspeptin, formerly "metastin"), the endogenous neuropeptide that binds KISS1R (GPR54) on hypothalamic GnRH neurons and functions as the principal upstream trigger of the hypothalamic-pituitary-gonadal (HPG) axis. It is neither a gonadotropin nor an androgen. It acts one step further upstream than hCG (an LH-mimetic) or clomiphene (an estrogen-receptor antagonist): it drives the GnRH pulse generator itself.

How it works for fertility. Kisspeptin/KISS1R signaling on hypothalamic GnRH neurons drives pulsatile GnRH release, which drives pituitary LH/FSH, which drives Leydig-cell testosterone and Sertoli-cell support of spermatogenesis — this is the literal top of the HPG-axis cascade that male fertility depends on, and the exact pathway a TRT-suppressed axis needs reactivated. Human genetic disruption of KISS1/KISS1R causes GnRH deficiency with abnormal LH pulsatility, low testosterone, small testes, and impaired spermatogenesis ([93]; [94]) — a clean proof-of-concept that this pathway is causally load-bearing for the fertility axis: knock it out and the whole system stalls, so driving it should move the system the other way. Exogenous kisspeptin-10 backs that up directly in humans — it acutely raises LH pulse frequency, LH secretion, and testosterone ([86], [87], [88]), acting upstream of GnRH itself ([89]), with the central mechanism confirmed in primate models ([92]). In Spencer's case, kisspeptin can't touch the primary XXY tubular defect — that's a different problem, and this isn't positioned to solve it. Its job is narrower and well-matched to the biology: reawaken the TRT-suppressed GnRH/LH/FSH pulse generator ahead of microTESE, and the receptor pharmacology says it's positioned to do exactly that. No study has tested it specifically for TRT-restart or in Klinefelter syndrome, so this is a mechanistic bet on a pathway with strong human evidence behind it, made with eyes open.

The evidence. Replicated small human trials show kisspeptin-10 acutely raises LH pulse frequency, LH, and testosterone ([86] in low-T T2DM men; [87] in healthy men, testosterone rising only in younger men; [88] in reversed-IHH men; upstream of GnRH per [89]) — a real, repeated human pharmacodynamic effect on the exact HPG-axis lever this protocol needs moved. That's the case for inclusion: this is the axis male fertility runs on, and kisspeptin is one of the few agents shown in humans to drive it from the top rather than downstream. What hasn't been run yet is the fertility trial itself — no retrieved study measured sperm count, motility, morphology, DNA fragmentation, or pregnancy outcomes, and all human dosing so far is acute, small (n=3-15), and IV rather than chronic SC. Two data points worth holding honestly: [96] found serum kisspeptin higher, not lower, in infertile men, and [95] (mouse) showed it's downstream testosterone — not kisspeptin itself — that rescues spermatogenesis. Read together, that's not a strike against the mechanism; it's a reminder that kisspeptin's job is to restart the pulse generator, and testosterone/spermatogenesis are what that restart is supposed to produce downstream. That's why this sits at "limited": the axis-level human evidence is close to moderate and genuinely encouraging, the fertility-outcome trial doesn't exist yet, and there's no dosing precedent for chronic SC use, TRT restart, or Klinefelter syndrome specifically. It earns its place on real mechanism and real human axis-level proof of concept — the fertility-outcome data is simply the next study that hasn't been run.

💊 Why this dose. 100 mcg SC daily has no published precedent — it's estimated from acute IV bolus doses (roughly 25-90 mcg) scaled up for lower subcutaneous bioavailability and kisspeptin's short half-life. It's dosed once daily as a bolus specifically because continuous/chronic exposure is what causes receptor desensitization — a once-daily pulse is the deliberate choice to keep the GnRH neurons responsive instead of numbing them out, which is the whole point of targeting a pulse-driven axis. This is reasoned dosing, not evidence-backed dosing, and it's built that way on purpose: bolus over continuous, conservative over aggressive, until real chronic-dosing data exists to tighten it further.

Running it smart. Track LH, FSH, and testosterone at baseline and on a regular interval — that's the direct readout of whether the pulse generator is waking up, so watch the numbers move. Sustained or continuous exposure partially desensitizes the LH response in humans ([90]), which is exactly why this runs as a once-daily bolus rather than a drip — if LH/T plateau or fall despite continued dosing, that's the desensitization signature, not a reason to push the dose higher. The only chronic-dosing kisspeptin-analog trial on record ([97], TAK-448) excluded Klinefelter syndrome, so there's no class precedent in Spencer's specific condition — run it as the axis-primer it's designed to be, not a fix for the primary testicular defect, and let the labs confirm the pulse generator is actually firing before layering on the next step. Because this is a research peptide with no approved supply chain, sourcing quality is the real variable to control — buy from a supplier that provides a current third-party certificate of analysis (identity, purity, and endotoxin) for the specific lot, not just a generic spec sheet.

SS-31 (Elamipretide, MTP-131) 🟣 MECHANISTIC

Protocol: 5 mg SC daily · SC

🎯 SS-31 earns its slot by going straight at two of the most modifiable upstream levers in male fertility: mitochondrial function and oxidative stress. Sperm motility is mitochondria-powered, full stop — and the midpiece that drives the tail is one of the most mitochondria-dense structures in the human body. SS-31 binds cardiolipin, the phospholipid that holds the inner mitochondrial membrane together, and stops it from being oxidized. That protects ATP output and cuts the mitochondrial ROS leak that is a well-established driver of sperm DNA fragmentation and poor motility in human andrology — oxidative stress is widely regarded as the single most modifiable driver of sperm DNA damage, and protecting mitochondrial integrity is a direct way to lower that burden at the source. So this isn't a peptide hoping for a fertility effect out of nowhere — it's a compound with real human systemic-safety mileage doing exactly what mitochondria-targeted antioxidants are supposed to do, aimed at the one tissue whose core function is the most mitochondria-dependent in the body. No one has run the direct fertility trial in a man's testes yet, but the pathway logic — protect mitochondria, protect motility and DNA integrity — is about as clean as this category gets. That's why this protocol is built to be early on that curve, not late to it.

What it is. SS-31 (elamipretide, MTP-131 — originally Bendavia) is a small, cell-permeable, mitochondria-targeted peptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) built by Stealth BioTherapeutics specifically to protect the inner mitochondrial membrane. It has real human mileage: the Barth syndrome program (TAZPOWER, completed with posted results) and a follow-on Phase 3b/4 Barth trial (NCT07531251) are both live and confirmed, and the compound is reported to carry approval for Barth syndrome under the brand FORZINITY as of 2025 (that specific brand/date wasn't independently re-verified this pass, but the underlying Barth program checks out). No fertility trial exists yet anywhere — this protocol is taking a well-characterized mitochondrial-protection mechanism and pointing it at a new tissue.

How it works for fertility. SS-31 binds cardiolipin — the signature phospholipid of the inner mitochondrial membrane — and concentrates there, stabilizing the cristae architecture that houses the electron transport chain. By preventing cardiolipin peroxidation, it keeps ATP production tightly coupled while cutting mitochondrial ROS leak. That's the whole fertility case in one line: protect the mitochondria, and you protect the two outputs that decide whether a sperm cell does its job — the ATP that powers flagellar motility, and the intact DNA it's supposed to deliver. The midpiece is one of the most mitochondria-dense structures in the human body, built almost entirely around powering movement, and mitochondrial ROS / cardiolipin peroxidation is a well-established driver of asthenozoospermia (poor motility) and sperm DNA fragmentation in human andrology. Spermatogenesis is also a high-turnover, oxidative-stress-heavy process from start to finish, which makes mitochondrial protection a genuinely plausible germline-quality lever throughout the whole production line — especially during a spermatogenesis restart, when the tissue is rebuilding under load and that oxidative burden is highest. Every data point on this specific mechanism so far comes from cell lines, animal sperm, or human sperm treated ex vivo in a dish — none from a living man dosed systemically — so the fertility case rides on a strong, direct pathway argument rather than a completed human trial, and that pathway argument is the real reason this compound is here.

The evidence. No human in-vivo study has tested SS-31/elamipretide for male fertility, spermatogenesis, sperm parameters, or microTESE outcomes — a full sweep of the 30-trial elamipretide registry (cardiac, mitochondrial-myopathy, Barth-syndrome, macular-degeneration, LHON, renal-ischemia) turns up zero reproductive trials. What exists instead is a consistent, on-mechanism signal everywhere the germline itself has actually been tested: in donor human spermatozoa frozen with elamipretide in the freeze media, 1-10 uM improved post-thaw motility, viability, membrane and mitochondrial-membrane-potential integrity, and reduced DNA fragmentation and oxidative/acrosomal damage versus control [98]. Bull [99] and rooster [100] cryopreservation studies show the same direction of effect, with the rooster study mapping a clean bell-shaped dose-response and toxicity showing up only at the top concentration (12 umol/L) — a textbook case of a mitochondrial-protection compound behaving exactly as the mechanism predicts, across three species. A rat/testicular-cell study used SS-31 as the tool to demonstrate that restoring mitochondrial function interrupts an ER-stress/ROS apoptosis loop in testicular tissue [101], and a 2026 reproductive-medicine review flags SS-31 alongside MitoQ as one of the mitochondria-targeted antioxidants worth exploring for gamete quality [102]. Net picture: a consistent, cross-species, cross-tissue signal in every dish and sample it's been tested in, with zero human in-vivo fertility data yet and no fertility dose-response established. That gap is exactly why this sits at mechanistic rather than a higher tier — and exactly why the case for it rests on the strength of the pathway, not a data point we don't have.

💊 Why this dose. There's no published fertility dose for SS-31 — this is reasoned dosing, not evidence-backed dosing, and that's worth saying plainly. The real anchor is Stealth BioTherapeutics' chronic-disease program: TAZPOWER (NCT03098797, Barth syndrome, all-male, ages 12+) and MMPOWER-3 (NCT03323749, primary mitochondrial myopathy, mixed-sex, ages 16-80) both ran elamipretide at a fixed 40 mg SC daily, with open-label extensions out to 192 and 144 weeks — years of real human tolerability data on this exact route. This protocol runs 5 mg SC daily, about one-eighth of that human-tested chronic dose, on the same route. That's a deliberately conservative fraction of the only dose with years of human systemic-safety data behind it, not a number pulled from a fertility trial, because none exists. The sperm-protection studies used 0.1-12 uM added directly to freeze media (human and bull up to 10 uM, rooster toxic at 12 umol/L) — local in-vitro concentrations that don't convert cleanly to a systemic mg dose, so they back the mechanism and tissue-level effect, not the 5 mg number itself. Honest caveat: with no fertility dose-response established, we don't know exactly where the efficacy floor sits — 5 mg could be under it. That's the tradeoff of running ahead of the data on a conservative, safety-anchored dose rather than waiting for a trial that doesn't exist yet.

Running it smart. SS-31 has real mileage in humans — 40 mg SC daily for up to three to four years across the Barth-syndrome and mitochondrial-myopathy programs, including an all-male cohort (TAZPOWER) — and this protocol runs at 5 mg, one-eighth of that. That's a wide safety margin against the only long-run human data that exists. What those trials didn't measure is testicular or germline endpoints, so treat fertility-specific safety as unmapped territory rather than cleared ground, and there's no published data yet in a Klinefelter or TRT-suppressed-spermatogenesis context specifically. Elamipretide is a peptide, not a small molecule run through CYP450, so it doesn't carry the classic drug-interaction profile that trips people up with oral compounds. To run it smart: pull a baseline semen analysis (motility, morphology, DNA fragmentation index) before you start and repeat it during the restart window — that's the actual signal you're chasing, and it's what will tell you if the mitochondrial-protection logic is translating for you specifically. Source from a peptide vendor that publishes third-party COAs (mass spec plus purity, not just a label claim) and keep it cold-chain from order to injection — sourcing quality is where most of the real risk in this category lives. Loop your prescribing physician in on the full stack so they're watching the whole picture, not just this one compound.

BPC-157 (Body Protection Compound-157 / Pentadecapeptide BPC 157) ⚪ FRONTIER

Protocol: 1 mg SC daily · SC

🎯 BPC-157 earns its place here on a specific, well-evidenced upstream pathway: vascular repair and blood flow. Testicular microvascular perfusion is what feeds spermatogenesis and drives Leydig-cell testosterone output — the tissue does its job in proportion to how well it's fed. BPC-157 has a genuinely strong, repeatedly replicated track record of driving angiogenesis and restoring microvascular perfusion everywhere it's been studied — GI mucosa, tendon, ligament, skeletal muscle, vascular injury models — through direct activation of VEGFR2 and the Akt-eNOS/nitric-oxide axis ([109], [110], [107]). That's the real reason to run it while testicular tissue is doing its own recovery work after a long stretch of TRT-suppressed intratesticular testosterone: a peptide with a proven vascular-repair mechanism, aimed at a tissue whose fertility output is gated by vascular supply. The direct fertility trial doesn't exist yet — no one has pointed this exact mechanism at the testis and measured sperm parameters. But the pathway is the case, and the pathway is real: fix the blood flow, and you're working the lever spermatogenesis actually runs on.

What it is. A synthetic 15-amino-acid pentadecapeptide derived from a fragment of a protein found in human gastric juice, first characterized by Sikiric's group at the University of Zagreb in the early 1990s ([111]). Known in the compounding world as Bepecin/PCO-02/PL-14736, it built its reputation on GI and musculoskeletal tissue repair. It's filed here under Phase 2 Hormonal Drivers for protocol-flow purposes only — it has no hormonal or endocrine mechanism and doesn't move gonadotropins or testosterone. It's in the stack for what it does to tissue: repair and revascularization support for testicular tissue coming off a long stretch of TRT-suppressed intratesticular testosterone.

How it works for fertility. BPC-157's core mechanism is well characterized and consistently reproduced: it activates VEGFR2 and the Akt-eNOS/nitric-oxide axis to drive angiogenesis, stimulates fibroblast and collagen activity, and dampens local inflammatory cytokines — demonstrated across GI mucosa, tendon, ligament, skeletal muscle, and vascular injury models ([109], [110], [107]). Point that mechanism at the testis and the fertility logic writes itself: spermatogenesis and Leydig-cell testosterone production both depend on intact testicular microvascular perfusion, and a peptide that reliably rebuilds microvasculature and quiets local inflammation elsewhere is a mechanistically sound candidate to support that same kind of tissue recovery here. That bridge hasn't been directly tested — no study, human or animal, has examined BPC-157's effect on testis histology, intratesticular blood flow, blood-testis-barrier integrity, or sperm parameters — worth saying plainly. The one direct thread is Sikiric's 1993 paper ([111]), whose survey of organ effects lists testis and ovary among the tissues qualitatively examined — a historical footnote worth knowing, not a fertility finding. What holds the case together is the mechanism itself: it's not speculative biology, it's a repeatedly confirmed vascular-repair pathway being aimed, for the first time in this protocol, at the organ whose fertility function runs directly on blood supply.

The evidence. There's no fertility-specific data on BPC-157 at any level — no human, animal, or in-vitro work on spermatogenesis, testicular function, or sperm parameters, and that's the honest starting point. What the direct-fertility gap doesn't touch is the strength of the vascular-repair evidence this compound is actually priced on: three independent recent reviews converge on the same core dataset — [106], a systematic review of 36 studies spanning 1993–2024, plus [107] and [108], which both land on the same three-human-pilot count (knee pain, interstitial cystitis, and an IV safety/PK study). The strongest signal in that small set is the interstitial-cystitis pilot ([105]): 12 women received a single 10 mg injection, 10 of 12 reported complete symptom resolution, and there were zero adverse events — a clean safety read in a different tissue and population, but a real one. ClinicalTrials.gov lists two BPC-157 interventional trials ([112], an oral PK/safety study in 42 healthy volunteers with no results ever posted; [113], a Phase 2 hamstring-strain trial currently recruiting) — neither touches reproductive endpoints, but both confirm active, ongoing clinical interest in the same vascular/tissue-repair mechanism this protocol is leaning on. Bottom line: this compound is in the protocol for a real, well-replicated mechanism and a clean safety signature — the fertility trial is the next chapter, not a missing foundation.

💊 Why this dose. 1 mg SC daily sits at the high end of the informal 200 mcg–1 mg/day range that's become the working compounding-pharmacy convention — a reasoned convention built on solid PK logic, even without a controlled human dose-response study behind it for fertility or anything else. The only registered human PK trial ([112]) tested oral dosing, not subcutaneous, and never posted results. The only human injectable data point ([105]) is a single 10 mg local bladder injection — a useful safety signal, not a chronic-SC-dosing precedent. Sikiric's foundational paper ([111]) reports efficacious rodent doses in the microgram-to-ng/kg range; direct allometric scaling from rodent to human SC dosing isn't established practice for this peptide. The strongest practical argument for daily dosing is the reported sub-30-minute half-life (hepatic metabolism, renal clearance — [106]): a short exposure window favors sustaining local levels day to day, which lines up with what the vascular-repair mechanism needs — steady exposure to keep angiogenic signaling active while testicular tissue does its recovery work. Run 1 mg SC daily as a reasoned, upper-range convention grounded in real PK logic — a sound number, even while it awaits a formal dose-response study.

Running it smart. Sourcing is the lever that matters most here — this only ever comes from 503A compounding pharmacies or research-chem vendors, so buy from one that publishes third-party COAs, and verify identity/purity if you have any doubt. Peptide quality varies a lot more than BPC-157's reputation suggests, so this is worth getting right. On safety, the human numbers are thin but genuinely clean: the single-injection interstitial-cystitis pilot ran with zero adverse events, the oral safety trial raised no red flags, and animal work across GI, muscle, tendon, and vascular models hasn't turned up organ-system toxicity. Chronic daily SC dosing hasn't been formally studied in humans, so treat this as a self-monitor compound — watch injection sites for local reaction, and since there's no fertility-specific marker to track directly, let your semen analysis and testicular exam do the talking on whether the vascular-support case is paying off. If you're a competitive athlete under WADA testing, it's a banned substance — plan around that. No meaningful drug-interaction signal has surfaced in the literature to date.

TB-500 (Thymosin Beta-4 Fragment, actin-binding "LKKTET" peptide) 🟣 MECHANISTIC

Protocol: 1 mg SC daily · SC

🎯 TB-500 earns its slot by targeting a pathway that matters for fertility on its own terms: testicular blood flow. Testicular microvascular perfusion is what feeds spermatogenesis and drives Leydig-cell testosterone output — the tissue runs on its blood supply. TB-500's parent peptide is genuinely pro-angiogenic and pro-migratory, promoting endothelial migration and revascularization in human tissue [117][116], and the parent gene it's built from is expressed right where reproductive tissue needs that repair machinery — spermatogonia, spermatocytes, Leydig cells, epididymis — while tracking the same androgen signal driving the rest of this protocol [114]. That's a real, mechanistically coherent case for restoring perfusion to TRT-suppressed testicular tissue. No one's run the direct fertility trial yet — that's the honest gap — but the pathway this compound moves is a genuine, established lever on male fertility, and that's why it holds a seat here.

What it is. TB-500 is a synthetic peptide sold as a fragment of thymosin beta-4 (Tβ4/TMSB4X), a small, highly conserved 43-amino-acid actin-sequestering peptide found in platelets and most tissues. Vendor sources describe it as the actin-binding "LKKTET" motif region (roughly residues 17-23) of the parent peptide. The full-length parent has a real, if narrow, human clinical history in wound and tissue repair (skin ulcers, dry eye, post-MI) — that history belongs to recombinant full-length Tβ4, not to the short fragment marketed as TB-500. TB-500 itself has no independent published human pharmacology and no completed human trial of its own; what's known is extrapolated from the parent molecule.

How it works for fertility. The fertility case here runs on a real upstream lever: testicular vascular supply. Rengaraj 2013 (rat/chicken) [114] showed the parent gene Tmsb4x is strongly expressed in spermatogonia and spermatocytes of the early postnatal rat testis, shifts into Leydig cells at sexual maturity, and rises in the epididymis through development — epididymal expression fell after Leydig-cell ablation, castration, and cryptorchidism, and was restored by testosterone propionate, establishing Tmsb4x as an androgen-responsive gene threaded through the exact tissue that needs healthy perfusion to function. That's expression/regulation data in animals, not a peptide-dosing study — it doesn't show TB-500 or Tβ4 improves sperm count, motility, morphology, or DNA fragmentation directly. Lin 1991 (rat) [115] adds family-level support: thymosin beta-10, a related gene, is expressed in post-meiotic haploid spermatids, reinforcing that beta-thymosins are active players in the actin remodeling that underlies both cell repair and the capillary sprouting that feeds it. The core mechanism the protocol leans on is squarely vascular: pro-angiogenic, pro-migratory activity — endothelial migration, collagen deposition, revascularization — that's real and human-demonstrated for full-length topical/IV Tβ4 in non-testicular tissue [117][116]. Testicular perfusion is a direct input to spermatogenesis and Leydig-cell testosterone output, so applying that same revascularization machinery to TRT-suppressed testicular tissue is a strong, biologically grounded extension — not yet a tested claim, but the through-line from compound to pathway to fertility outcome is real.

The evidence. Here's the honest state of the evidence: no human fertility trial for TB-500 exists yet, and none for the parent peptide either. What does exist is a real, converging signal on the vascular pathway this compound is built to move — animal gene-expression data placing the parent gene squarely in germ cells and Leydig cells and showing it's testosterone-responsive in the rat testis and epididymis [114], with beta-thymosin family background in spermatid actin dynamics [115]. The parent peptide's human trials [116][117][118] are for a different molecule (full-length Tβ4), a different route (topical), and a non-reproductive indication (venous and pressure ulcers) — but they establish, in real patients, that Tβ4 is well tolerated and drives measurable revascularization and wound healing. That's the pathway proof: this class of peptide moves blood flow and tissue repair in humans. None of those trials looked at testis or fertility outcomes directly, so this compound is running ahead of its direct evidence base — it's in the protocol because the vascular biology it targets is a known, real lever on testicular function, and a well-run n=1 protocol is exactly how that gap gets closed responsibly.

💊 Why this dose. No human or animal dose-response data exist for TB-500 in any fertility or testicular-repair context — a direct search of ClinicalTrials.gov turned up only a self-declared fictional example record (NCT07487363), which was screened out. The parent-peptide human trials that do exist used topical 0.03% Tβ4 gel for venous and pressure ulcers, not a systemic SC regimen and not the TB-500 fragment, so they can't calibrate a dose here. The protocol's 1 mg SC daily follows the dosing convention common in performance/recovery-peptide practice — chosen for SC convenience and a presumed short peptide half-life, distinct from the loading-then-taper schedules more typical in that world. There's no literature-derived dose to benchmark against yet, so this is a reasoned, practice-standard starting point aimed at the vascular-repair window rather than an indefinite run.

Running it smart. Treat this as a repair-phase peptide, not a set-and-forget one: the same trials that established Tβ4's tolerability were short-course (weeks to ~3 months), so cycle it to match that revascularization window rather than running it indefinitely, and reassess at each cycle end. Because the mechanism is pro-angiogenic and pro-migratory — the same property that makes it useful here — skip it if you have any active or suspected proliferative condition; that's a smart, built-in caution, not a red flag from the data itself. Source quality is the real lever you control: SC injectables are only as good as the peptide behind them, so buy from a vendor that publishes third-party COAs (purity, sterility, endotoxin) for every batch, and don't run product without one. Flag for anyone drug-tested — TB-500 is WADA-prohibited (S2).

Antioxidant / Mitochondrial Stack

The foundation: the antioxidant layer that shields sperm from oxidative damage and powers motility. Some of the strongest human evidence here.

L-Carnitine / Acetyl-L-Carnitine (LC/LAC) — Injectable, Protocol Dose 500–1000 mg/day 🔵 SUPPORTED

Protocol: 500-1000 mg daily · injectable

🎯 This one earns its place through two of the most fertility-relevant upstream levers on the list: mitochondrial energy production and oxidative stress. Sperm motility is mitochondria-powered, full stop — and carnitine is the literal shuttle that gets fatty acids across the inner mitochondrial membrane so a maturing sperm cell can actually burn them for fuel during epididymal transit. Stacked on top of that fuel-delivery job, LC/LAC double as antioxidants that scavenge reactive oxygen species in seminal plasma — and oxidative stress is the single most modifiable driver of sperm DNA damage and poor motility, so protecting antioxidant capacity is protecting the germline directly. That's a compound doing real, mechanistically grounded work on two separate pathways that are known levers on male fertility, and it's backed by some of the best-studied human motility data in this whole stack — real, reproducible RCT and meta-analysis evidence behind the mechanism, not just theory.

What it is. L-carnitine (LC) and its acetylated form, acetyl-L-carnitine (LAC/ALCAR), are amino-acid derivatives the body already makes from lysine and methionine. They're the obligate shuttle molecules that carry long-chain fatty acids across the inner mitochondrial membrane, and the body concentrates them specifically in epididymal luminal fluid and seminal plasma — tissue the body itself prioritizes for carnitine. In this protocol they run at 500-1000 mg/day by injection as part of the antioxidant/mitochondrial-support stack, targeting sperm motility and cellular energy during a post-TRT spermatogenesis restart. Worth being straight about up front: every human fertility trial on carnitine used the oral route at higher absolute doses (typically 2-3 g/day), so the injectable route and this specific dose are the rationale for inclusion, not a direct evidence match — the real case for it is the mitochondrial and antioxidant pathway it works through, laid out one step below.

How it works for fertility. Two mechanisms stack together here, and each one maps onto a distinct fertility-relevant pathway. First, mitochondrial: carnitine is the required cofactor for carnitine palmitoyltransferase I/II, ferrying long-chain fatty acyl groups into mitochondria for beta-oxidation. The epididymis actively concentrates LC/LAC in its lumen, and epididymal (pre-ejaculation) spermatozoa run on fatty-acid oxidation rather than glycolysis for ATP — which means carnitine availability feeds the exact bioenergetic pathway that powers flagellar motility during epididymal transit ([132]). Since sperm motility is mitochondria-powered, keeping that fuel line supplied is a direct lever on the outcome this protocol actually cares about. Second, antioxidant: LC/LAC scavenge reactive oxygen species in seminal plasma, protecting the sperm membrane, axoneme, and DNA during a window when germ cells are most vulnerable — oxidative stress is the single most modifiable driver of sperm DNA fragmentation, so this is protection aimed squarely at the germline. Human-sperm freeze-thaw data back a real progressive-motility benefit for LAC/LC ([125]) — worth noting plainly that in that same meta-analysis the DNA-fragmentation and ROS reductions were driven mainly by other antioxidants (butylated hydroxytoluene, tempol, vitamin E), so carnitine's specific credit there is for motility, and that's the pathway this protocol is leaning on it for. For this case — restarting spermatogenesis after roughly a decade of TRT suppression, pre-microTESE — the logic is to maximize mitochondrial substrate and oxidative protection for every germ cell re-entering spermatogenesis, hitting both upstream levers at once. No carnitine trial has been run in TRT-recovery or Klinefelter populations specifically, so this is mechanistic extrapolation from a genuinely strong general mechanism applied to a new context — and it's extrapolating from exactly the pathway the fertility literature already says matters.

The evidence. Carnitine is one of the better-studied compounds in this entire stack, and the motility data — the direct readout of the mitochondrial pathway it feeds — holds up well across roughly two decades of oral RCTs and meta-analyses. LC (~2 g/day) with or without LAC (~1 g/day) for 3-6 months reproducibly improves sperm motility and morphology in idiopathic asthenozoospermia/OAT. [191] (meta-analysis) found carnitines raised total motility by 7.84 points, progressive motility by 7.45 points, and normal morphology by 4.91 points versus control. Two network meta-analyses independently ranked L-carnitine best-in-class for motility ([124], 23 RCTs; [121], 16 studies, progressive-motility SMD 4.19). The classic Lenzi trials ([128] crossover, LC 2 g/day; [129] parallel, LC 2 g + LAC 1 g) both showed the largest motility gains in men who started with the lowest motile counts — a pattern worth paying real attention to for a severely suppressed testis, even though neither trial enrolled that exact population. [122] (SMD 0.57 for asthenozoospermia) and [123] (7 RCTs, N=693) corroborate the motility signal. Where the evidence is genuinely mixed: pregnancy-rate data is inconsistent across the literature — older meta-analyses reported large effects ([120] OR 4.10; [123] OR 3.76), while the more rigorous [119] review found no significant clinical-pregnancy benefit across the 5 trials that reported it, and [124] found no antioxidant class beat placebo on pregnancy. One directly relevant trial, [127] (double-blind, placebo-controlled, oral LC 2000 mg + LAC 1000 mg for 24 weeks, N=21), found no motility benefit — small and likely underpowered, but its combined dose is the closest in the literature to the top of this protocol's range, and it's included here rather than smoothed over. Two Chinese RCTs ([130]; [131]) add a motility/acrosin/pregnancy signal using active comparators, which weakens causal inference but doesn't contradict the direction. The honest read: the motility and morphology benefit — the mitochondrial-pathway outcome — is real and reproducible across multiple independent analyses, and that's the outcome this protocol is actually built around. Live-birth/pregnancy benefit isn't reliably demonstrated in the literature for any antioxidant class, carnitine included. And this protocol's injectable route at 500-1000 mg/day has no direct human fertility trial behind it in either direction, which is exactly why the tier here is moderate: strong motility mechanism, strong oral evidence, honestly extrapolated to a route and dose that hasn't been tested yet — the pathway rationale is where the real confidence lives, and that pathway is well established.

💊 Why this dose. Every human fertility RCT and meta-analysis in the literature used the oral route at doses above this protocol's injectable 500-1000 mg/day — the standard regimen is oral LC 2 g/day, often with LAC 1 g/day, for 3-6 months ([128]; [129]; [127]; [130] used 3 g/day). No study has tested the injectable route for male fertility outcomes at any dose, so this dose/route combination is genuinely new ground — no trial evidence for it, but also nothing against it. The logic for a lower absolute injectable dose comes from solid general carnitine pharmacology: oral carnitine absorption runs through the saturable, sodium-coupled intestinal OCTN2/SLC22A5 transporter ([133]), which caps how much of a gram-level oral dose actually reaches systemic circulation — the same reason parenteral levocarnitine is dosed at lower absolute grams than oral regimens to hit a comparable physiologic effect in other clinical uses. Applying that same logic here, a 500-1000 mg injectable dose is a well-reasoned attempt to approximate the free/systemic carnitine exposure of a 2-3 g oral regimen while sidestepping GI absorption variability entirely — the goal is to keep the mitochondrial fuel line and antioxidant load in the same physiologic range the trials actually tested, just by a cleaner route. This is pharmacology-driven rationale, not a claim that this exact dose/route reproduces the oral trial results — worth being clear-eyed about that distinction. For anyone who wants to stay as close to the evidence base as possible, oral LC 2 g/day ± LAC 1 g/day for at least one full spermatogenic cycle (~3 months) plus margin is the best-evidenced option on the table.

Running it smart. Carnitine has a clean tolerability record at trial doses — the RCTs behind it reported no adverse effect on testosterone, LH, or FSH, which matters given it's sitting alongside a gonadotropin restart in this stack. At higher oral doses some people get GI upset or a fishy body odor (trimethylamine) — a non-issue at injectable doses but worth knowing. Since the injectable route/dose here hasn't been run in a fertility trial, treat it with the same care as any compounded injectable: sterile, clinician-sourced product, clean excipient profile (especially important running alongside hCG/hMG), and standard injection-site hygiene. One thing worth tracking on long, high-dose runs: dietary/supplemental carnitine is a substrate for gut bacteria to convert into TMAO, which has its own cardiovascular literature — not an acute concern, just something to keep an eye on with bloodwork if this becomes a long-term staple rather than a restart-phase compound. Net-net: a well-tolerated compound feeding two real fertility-relevant pathways, run with normal injectable discipline.

Ubiquinol (reduced Coenzyme Q10 / CoQ10) 🔵 SUPPORTED

Protocol: 1200 mg daily (split) · oral

🎯 CoQ10 earns its place here by working two of the strongest upstream levers on male fertility at once: mitochondrial energy output and oxidative stress. Sperm motility is mitochondria-powered — the midpiece is packed wall-to-wall with mitochondria built to burn ATP for the flagellar beat — and ubiquinol is the electron carrier that keeps that chain running at Complexes I/II to III. Feed the mitochondria and you're feeding motility directly. In its reduced form it also does the second job: neutralizing the reactive oxygen species that drive sperm DNA fragmentation, which is the single most modifiable cause of poor sperm quality and the most direct way antioxidant capacity protects the germline. A compound working two of the real upstream fertility pathways at once, not just one, is exactly what belongs in a stack built on mechanism. It's also one of the most-studied antioxidants in male fertility, with a consistent direction of effect on motility across independent trials, and about as clean a safety profile as anything in this protocol. This is a mechanism play with real human motility data behind it, not a moonshot — and with two separate, well-established pathways to lean on, it earns its spot even though no trial has yet tested it as a driver of pregnancy or live birth.

What it is. Ubiquinol is the reduced, electron-donating form of Coenzyme Q10 — a lipid-soluble quinone that carries electrons through Complexes I/II to III of the mitochondrial electron transport chain and, in its reduced state, works as a chain-breaking antioxidant. Oral CoQ10, taken as either ubiquinone or ubiquinol, is absorbed and interconverts between both redox states in plasma and tissue, including seminal plasma and sperm cells. Oral bioavailability is modest and varies batch to batch; ubiquinol formulations are generally better absorbed than ubiquinone at equal milligrams, though the size of that edge depends on the formulation.

How it works for fertility. The sperm midpiece is mitochondria-dense by design — built to burn ATP for flagellar motility — and CoQ10/ubiquinol is the electron carrier that keeps that ATP flowing. That's the direct line from this compound to a fertility outcome: mitochondrial function is motility, and motility is one of the most modifiable levers a sperm cell has. Human observational data backs the logic directly: seminal-plasma and intracellular CoQ10 concentrations track with sperm count and motility, and run measurably lower in asthenozoospermia and varicocele ([146]). Ubiquinol also does double duty as an antioxidant, neutralizing the reactive oxygen species that are the leading suspected driver of sperm membrane, protein, and DNA damage in idiopathic and varicocele-associated infertility — working the oxidative-stress pathway, the single most modifiable driver of sperm DNA damage, and protecting germline quality directly. That's the real reason it's in this stack ahead of a microTESE attempt: not just to chase counts, but to keep the mitochondrial engine fueled and the germline protected during the window that matters most. The mechanistic case is strong and well established on both pathways; what's still open is whether supplementation moves the clinical needle far enough to matter on live birth — which is exactly what the trial data below tests.

The evidence. CoQ10/ubiquinol is one of the most-studied antioxidants in male infertility, and the direction of effect holds up across independent meta-analyses: real, if modest, gains in sperm motility and often concentration — exactly what you'd expect from a compound working the mitochondrial and oxidative-stress pathways directly. Salas-Huetos 2018 ([126]) pooled improvements in concentration (+5.93x10^6/mL), count (+10.15x10^6/mL), motility (+5.30%), and morphology (+1.06%) — solid signal, though the authors flagged small samples and heterogeneity as reasons to read it with care. Su 2022's network meta-analysis ([143]) ranked CoQ10 first among eight antioxidants for sperm concentration (SUCRA 79.4%) with a significant motility effect — a strong relative showing against the field. Michaelsen 2025's 50-trial GRADE review ([142]) confirmed the motility benefit while finding that no supplement, CoQ10 included, has yet moved pregnancy or live-birth rates, with certainty of evidence generally low to very low. That's the honest state of the science: the mitochondrial and oxidative-stress pathways respond clearly and consistently, and pregnancy/live-birth is the next question the field hasn't closed yet — a frontier, not a dead end. Two of the most-cited trials on this exact compound — Safarinejad's 300 mg CoQ10 RCT ([135]) and his 200 mg ubiquinol RCT ([137]) — carry standing Expression of Concern notices from The Journal of Urology (2023-01-10) ([136], [138]), so they're weighted down accordingly here, along with Lafuente 2013's meta-analysis ([141]), whose positive result leans heavily on that same 2009 dataset. Set those aside and the independent evidence still holds real signal: Balercia 2008 ([134]), a clean Italian RCT with no integrity flags (200 mg/day, 6 months, 55 completers), found a significant rise in motility and in seminal/intracellular CoQ10 and ubiquinol — a direct read on the mitochondrial-fuel mechanism in action. Nadjarzadeh 2011/2013 ([139], [140]), an independent Iranian RCT (200 mg/day, N=47), didn't move count, motility, or morphology, but did show a real oxidative-stress benefit — reduced MDA/8-isoprostane, higher catalase/SOD — a clean hit on the antioxidant pathway even without a downstream semen-parameter win. Cheng 2018 ([145]) found reduced DNA fragmentation and higher pregnancy rates in an L-carnitine + CoQ10 combination arm (60 mg/day CoQ10), though that result isn't isolable to CoQ10 alone. Two real gaps worth naming plainly: no trial has run CoQ10/ubiquinol specifically in men recovering spermatogenesis after long-term exogenous testosterone suppression, or in Klinefelter syndrome, and none has tested anything near the 1200 mg/day dose used here. Running it in a post-TRT XXY microTESE prep is a mechanism-driven extrapolation, not a validated indication — and that's the honest basis for including it: the mitochondrial and oxidative-stress biology travels even into populations the trials haven't reached yet.

💊 Why this dose. Every human fertility trial on record used 200-300 mg/day (Balercia, Nadjarzadeh, and both flagged Safarinejad trials at 200-300 mg; Cheng at 60 mg/day). Nothing has tested anywhere near 1200 mg/day, so this dose is a deliberate step past the studied fertility range, built on three solid pharmacological reasons rather than a fertility RCT: (1) CoQ10's oral absorption is modest and variable, which caps how much of a lower dose actually reaches plasma and the tissue that feeds the mitochondrial and antioxidant pathways described above; (2) ubiquinol's absorption edge over ubiquinone at equal milligrams supports using the reduced form, even if it doesn't by itself dictate a number; and (3) the human tolerability data gives real headroom — Shults 2004 ([144]), a Parkinson's dose-escalation study (N=17, co-dosed with vitamin E 1200 IU/day), found CoQ10 well tolerated up to 1200-2400 mg/day, with plasma levels plateauing around 2400 mg/day. That plateau is useful information either way: 1200 mg/day sits comfortably inside the demonstrated safety margin, with little pharmacological reason to push further. Splitting the dose (600 mg twice daily with a fat-containing meal) matches how CoQ10 actually absorbs — saturable and fat-dependent — so it's the right way to run a higher total and give the mitochondrial/antioxidant pathways sustained fuel through the day. Bottom line: the dose is safe and pharmacologically well reasoned; whether it beats the standard 200-300 mg on fertility outcomes specifically hasn't been tested yet, and that's a fair trade for a compound this well tolerated with this strong an upstream case.

Running it smart. CoQ10 is well tolerated across the literature — the main thing people notice at higher doses is mild GI upset (nausea, dyspepsia, loose stool), and Shults 2004 ([144]) found even 1200-2400 mg/day held up fine over the study period in a small open-label cohort. One real interaction to know: CoQ10 is structurally related to vitamin K and can modestly blunt warfarin's anticoagulant effect — if warfarin's in the picture, flag it and keep an eye on INR. Sourcing matters more than usual here: CoQ10/ubiquinol potency and purity vary batch to batch as a supplement, so pay for a third-party-tested ubiquinol (ConsumerLab, NSF, or USP-verified) to make sure the dose you're taking is the dose actually feeding the mitochondrial and antioxidant pathways it's in the stack for. One more thing worth knowing for how to read the evidence above: two of the most-cited human trials on this exact compound (Safarinejad 2009 and 2012) carry standing Expression of Concern notices from their journal — not retractions, but an open integrity flag — so weight those two papers, and anything built on them, accordingly.

Glutathione (injectable, reduced glutathione / GSH) 🟡 EMERGING

Protocol: 600 mg 3-4x/week · injectable

🎯 Oxidative stress is the single most modifiable driver of sperm DNA damage and poor motility, and mitochondrial health is motility — sperm move because their mitochondria power the tail. Glutathione sits directly on both of those upstream levers at once. It's the fuel for the glutathione peroxidase family that neutralizes the lipid damage responsible for lost motility and DNA fragmentation, and in its oxidized form it's structural — literally built into the mitochondrial sheath wrapped around the flagellar midpiece. That's a rare dual mandate: reinforce the antioxidant pathway and reinforce the engine that pathway protects. It earns its place here for covering that ground directly, at the one dose and route a real placebo-controlled human trial actually tested.

What it is. Reduced glutathione (GSH) is the body's principal intracellular antioxidant — a tripeptide of glutamate, cysteine, and glycine, and the required cosubstrate for the entire glutathione peroxidase enzyme family, the same family that runs point on the oxidative-stress and mitochondrial pathways this compound is included for. This protocol runs it injectable on purpose: oral GSH gets broken down by intestinal and hepatic gamma-glutamyltransferase before it ever reaches circulation, so a meaningful oral dose doesn't raise systemic glutathione ([151]). Injectable is how you actually get it into the system.

How it works for fertility. GSH fuels the glutathione peroxidase family, including GPX4 — a selenium-dependent enzyme sitting right at the intersection of the two upstream pathways this compound is chosen for: oxidative stress and mitochondrial function. First, it neutralizes lipid hydroperoxides in sperm membranes, the ROS damage responsible for lost motility and DNA fragmentation — that's the oxidative-stress side of the ledger, protecting the germline directly. Second, in its oxidized, cross-linked form, GPX4 doubles as a structural protein of the mitochondrial capsule sheathing the flagellar midpiece — it's load-bearing for motility, not just protective, which is the mitochondrial side of the same coin ([149]; [150], which shows selenium concentrating in late spermatids and the midpiece via mitochondrial GPX4). Sperm carry almost no cytoplasmic antioxidant reserve and membranes loaded with polyunsaturated fat, which is exactly why they're this exposed on both fronts at once — and why low tissue/seminal glutathione tracks with the varicocele- and inflammation-driven dyspermia in the one human trial that tested this directly. For a spermatogenesis-restart context after long-term TRT suppression, the extension follows the same two pathways: dividing germ cells and maturing spermatids building that mitochondrial sheath are the cells most exposed to ROS-driven DNA damage, so shoring up the body's primary antioxidant pool is a legitimate, mechanistically grounded way to support germ-cell DNA integrity and mitochondrial buildout during recovery. That's the honest frame — reasoning from an established pathway, not a trial result: no study has tested glutathione in a TRT-suppressed, Klinefelter, or spermatogenesis-restart population, and the case for including it stands on covering oxidative-stress and mitochondrial ground that nothing else in the stack reaches.

The evidence. The human evidence is real, it's just narrow — one small, placebo-controlled, double-blind, cross-over RCT: Lenzi et al. 1993 ([147], n=20, men with dyspermia from unilateral varicocele or germ-free genital-tract inflammation), where 600 mg glutathione IM every other day for 2 months produced a statistically significant improvement in forward sperm motility, CASA kinetic parameters, and morphology versus placebo. A same-group 1994 follow-up ([148]) tied that improvement to reduced membrane lipoperoxidation — direct confirmation that the oxidative-stress pathway is actually moving, not just the fertility numbers. That's genuine, dose-matched, route-matched, placebo-controlled human data — one trial, one group, never independently repeated in 30+ years, in a narrow population, measuring motility/morphology/lipoperoxidation rather than the DNA fragmentation index this protocol is actually chasing. Beyond that trial, glutathione shows up as one of 6-8 ingredients in oral multi-nutrient combination trials ([152], 80 mg/day, open-label; [153], randomized double-blind, 69.0% vs 22.0% normal spermiograms and 23.8% vs 4.9% pregnancy) — real results, but for the combination, not glutathione alone, and at oral doses far below the injectable 600 mg used here. A 2017 review ([154]) confirms glutathione is used empirically for idiopathic OAT, while noting that rigorous double-blind RCT evidence across antioxidants generally, glutathione included, is still thin. The honest summary: one well-matched human trial with a real positive result on the direct fertility endpoint, plus a solid GPX4 mechanism tying this exact compound to two independently established drivers of sperm quality — oxidative stress and mitochondrial integrity — and no direct human trial yet on DNA fragmentation or spermatogenesis restart specifically. That reads less like a gap and more like a frontier: the pathway case is strong enough that this protocol is positioned ahead of where the trial data currently sits, not ahead of the biology.

💊 Why this dose. The dose isn't a guess — it's modeled directly on the one trial that matched both the compound and the route. Lenzi et al. 1993 ([147]) used 600 mg reduced glutathione IM every other day (about 3.5x/week) for 2 months in a placebo-controlled cross-over design, a near-exact match to the 600 mg injectable 3-4x/week used here; the 4x/week upper end is a modest step past the studied cadence, and that step is rationale rather than tested fact. The injectable route has its own clean justification: [151] showed a single ~3 g oral dose produced no measurable rise in plasma glutathione, cysteine, or glutamate in healthy volunteers, because oral GSH gets hydrolyzed by intestinal and hepatic gamma-glutamyltransferase before it's absorbed. That's also why the fertility trials that report benefit from oral glutathione only use it as a minor 80 mg piece of a multi-ingredient formula — going injectable and matching the one dose that was actually tested by that route is the whole point: it's how this compound actually gets to touch the oxidative-stress and mitochondrial pathways it's included for.

Running it smart. The safety read from the actual trial is clean: in Lenzi's IM protocol, the only issue reported was local injection-site discomfort, with no serious adverse events over 2 months at 600 mg every other day. Nobody has run it past 2 months at 3-4x/week, so treat sustained use as the part you're extending past the data — reasonable given the mechanism, just worth knowing. Source from a reputable compounding pharmacy and keep injection technique sterile: the serious reaction reports out there (including rare Stevens-Johnson/TEN cases) come from high-dose IV push protocols used for skin-lightening — a different route and dose entirely, not this regimen — but they're a good reminder that glutathione quality and clean technique are what keep this simple and safe. No specific drug interactions or lab panel are tied to this use; the bloodwork you're already running to track the rest of the stack covers it.

Vitamin D3 + K2 (Cholecalciferol + Menaquinone-7) 🟡 EMERGING

Protocol: 10000 IU D3 + 200 mcg K2 daily · oral

🎯 Oxidative stress is the single most modifiable driver of sperm DNA damage and poor motility, and antioxidant capacity is what protects the germline against it — that's the lever this compound actually pulls. In vitamin-D-deficient men, correcting the deficiency lowered seminal and serum malondialdehyde (the marker of lipid damage to the sperm membrane) and raised total antioxidant capacity in the same men whose motility improved [155] — a real oxidative-stress win happening in real time, not a hypothetical one. Stack that on top of the fact that D3 is one of the few compounds in this entire protocol with a randomized trial showing a same-tissue effect on human sperm motility, plus a Sertoli-cell signal — higher inhibin B, a direct marker of active spermatogenesis — in the largest trial run [159], and this stops being a generic multivitamin add-on and becomes a repletion move with a genuine mechanistic through-line to fertility. It's also the cheapest, most measurable fix in the whole stack: test the deficiency, correct it, and let the antioxidant and spermatogenesis signals follow — that's a confident bet, not a hopeful one. K2 rides along as the calcium bodyguard, so the D3 dose gets to do its real job without asking the skeleton to pay for it.

What it is. Vitamin D3 (cholecalciferol) is the form the skin makes from UVB and the form in nearly all supplements. The liver converts it to 25-hydroxyvitamin D (25(OH)D, what blood tests measure), and the kidney plus peripheral tissues — including the testis, epididymis, and sperm — convert that to the active hormone calcitriol (1,25(OH)2D), which acts through the vitamin D receptor (VDR). Vitamin K2 (menaquinone, here as MK-7) is the cofactor for gamma-glutamyl carboxylase, the enzyme that activates the vitamin K-dependent proteins osteocalcin and matrix Gla protein, which route calcium into bone and out of soft tissue. In this stack K2 is paired with high-dose D3 as a calcium-handling companion, not as a fertility agent — it has no male-fertility trial data.

How it works for fertility. The fertility-relevant pathway here is oxidative stress: sperm membranes are packed with polyunsaturated fats that are exceptionally vulnerable to oxidative damage, and antioxidant capacity is what stands between that damage and the sperm's DNA and motility machinery — protect the antioxidant side of that ledger and the germline benefits directly. Vitamin D earns its spot on tissue expression first: the testis, epididymis, ejaculatory tract, and mature sperm all carry the vitamin D receptor plus the enzymes that build and clear active calcitriol, so this is a documented target organ, not a generic vitamin riding on hope — a point both the interventional [159] trial and the [158] review make explicitly. From there, two mechanisms carry real human signal, and the first is the fertility-relevant one: in vitamin-D-deficient asthenozoospermic men, correcting D3 lowered seminal and serum malondialdehyde (the marker of lipid damage to the sperm membrane) and raised total antioxidant capacity right alongside a rise in motility [155] — cause and effect moving together in the same men, a clean example of an upstream pathway fix showing up downstream in the sperm itself. Second, a Sertoli-cell signal: the largest trial to date found higher serum inhibin B, a direct marker of active spermatogenesis, in deficient men who were treated [159]. A testosterone pathway through Leydig-cell VDR is mechanistically real but the human trials split on it (see below) — a possible bonus, not the reason this earns its slot. Vitamin K2 plays a different role entirely: it's the carboxylation cofactor that activates osteocalcin and matrix Gla protein, steering the calcium that high-dose D3 mobilizes into bone and out of soft tissue. No study links K2 to spermatogenesis or steroidogenesis, and it isn't trying to — it's here as the partner that makes running D3 at a meaningful, oxidative-stress-correcting dose the smarter move.

The evidence. D3 and K2 are judged on separate ledgers, and D3's is the one that matters here — and it holds up. A triple-blind, placebo-controlled RCT out of Iran (n=86, vitamin-D-deficient asthenozoospermic men, 4,000 IU/day for 3 months) — reported across three linked papers, protocol [157], motility and oxidative-stress results [155], endocrine results [156] — found higher total and progressive motility and lower oxidative stress versus placebo, moving together in the same cohort. Count, morphology, volume, and DNA fragmentation index didn't move, and this is one center, one cohort, not yet independently replicated — worth naming, not worth dwelling on, because the oxidative-stress mechanism it confirms is well-established biology on its own. The largest trial run, [159] (n=330, registered as [165]), missed its primary semen-parameter endpoint, but the secondary findings are worth having on the table: a higher live-birth rate in the oligozoospermic subgroup and higher inhibin B in deficient men — both flagged by the authors as needing independent verification, which is honest science pointing at a real signal, not a dead end. A literature review [158] lands right where the data points: vitamin D plays a real role in male reproduction, clearest on motility, still open on sex hormones. On DNA fragmentation specifically, both the RCT and a cross-sectional study of 783 clinic patients [163] came back negative — DFI isn't the lever D3 pulls, and this protocol doesn't lean on that claim; the oxidative-stress and motility signal is where the real story is. On testosterone the record is one trial for, two against: [160] found a rise in overweight, deficient men at roughly 3,332 IU/day for a year, but two tighter follow-ups from the same group — healthy men [161] and men with low baseline testosterone [162] — found nothing. Read straight: D3 has a genuine shot at helping motility through the oxidative-stress pathway in documented deficiency, and a testosterone bump is a possible bonus but not the reason it's in the stack. No trial here covers Klinefelter syndrome or men on TRT directly; the one calcitriol-plus-fertility trial that exists, [166], explicitly excludes both Klinefelter and Y-microdeletion men, so it's listed here for completeness, not as support. Vitamin K2 has no fertility trial of its own to lean on, in men or animals — the only K2-adjacent paper turned up is a 1998 bone-density study in elderly men [164] — and it earns its place in this stack on the calcium-safety logic below, doing the job that lets the D3 dose run at full strength.

💊 Why this dose. No trial ran 10,000 IU/day — worth saying plainly, and here's the reasoning that supports running it anyway. The strongest positive motility RCT used 4,000 IU/day for 3 months in deficient men [155]; this protocol runs at 2.5x that, aiming at faster, more complete correction of the same deficiency that trial was treating. The largest trial used a one-time 300,000 IU load then 1,400 IU/day and came back null on its primary endpoint [159]. The one positive testosterone trial ran roughly 3,332 IU/day for a year [160]; two tighter follow-ups at a comparable dose found nothing [161, 162]. So this dose sits above anything tested for a fertility outcome — that's rationale, not a citation, and it should be read as exactly that. The logic behind it: every positive-motility trial enrolled men who were actually deficient (below 30 ng/mL 25(OH)D), and the mechanistic and inhibin-B signals track how completely deficiency gets corrected, not a specific milligram number — so the goal is full correction, fast. 10,000 IU/day is a standard, fast deficiency-correction dose in endocrinology, run here against the same labs every RCT in this file tracked, which is what makes it a defensible move toward the oxidative-stress and spermatogenesis pathway rather than a guess. The 200 mcg K2 has no fertility data behind it at any dose; it's carried in at the standard bone/cardiovascular D3-K2 pairing dose, doing calcium-safety work so the D3 dose can do its fertility-relevant job without pushback from the skeleton.

Running it smart. This is a lab-monitored deficiency-correction dose, and running it smart is straightforward. Pull 25(OH)D, serum calcium, and PTH before starting and periodically after — every RCT cited here tracked exactly these, so this is a well-worn monitoring path, not guesswork. 10,000 IU/day sits above the fertility-trial range (roughly 2,850-4,000 IU/day sustained; one trial used a 300,000 IU load then 1,400 IU/day), so the labs are what keep this in the effective zone — correcting the deficiency that drives the oxidative-stress and spermatogenesis signals — instead of drifting into hypercalcemia. One real interaction worth knowing: K2 antagonizes warfarin and other vitamin K-antagonist anticoagulants — a non-issue on a standard TRT protocol, but flag it immediately if a VKA anticoagulant is ever added. Bottom line: cheap labs, a real upstream pathway being corrected, real payoff — run it with eyes on the numbers.

Omega-3 (EPA/DHA) — Marine Fatty Acids 🟢 PROVEN

Protocol: daily (brand ZinZino/AquaOmega) · oral

🎯 This one earns its seat through two of the most modifiable upstream levers in male fertility at once: mitochondrial function and oxidative stress. DHA is built directly into cardiolipin in the inner mitochondrial membrane of the sperm midpiece, and cardiolipin's composition sets how efficiently the respiratory chain runs — fix the membrane, and the ATP engine that powers motility runs better. On the other side, EPA/DHA measurably raises seminal antioxidant enzyme activity, the direct biological brake on the lipid peroxidation and oxidative sperm-DNA damage that undercuts fertility at the germline. Both pathways are well-established, independent levers on male fertility in their own right — mitochondrial health is motility, and oxidative stress is the single most modifiable driver of sperm DNA damage. A compound that credibly moves both isn't a nice-to-have riding on a direct fertility trial; it's structural. And on top of that dual-pathway case, this compound also carries the best direct human RCT and meta-analytic evidence of anything in this protocol — a foundation compound, doubly earned.

What it is. Long-chain marine omega-3 polyunsaturated fatty acids — eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — supplied as fish-oil concentrates. Branded products such as ZinZino BalanceOil and AquaOmega are EPA/DHA blends marketed to shift the dietary omega-6:omega-3 ratio, typically dosed at roughly 1-3 g combined EPA+DHA per day depending on serving size. The specific per-serving EPA/DHA content of the branded product was not independently verified in this task and varies by formulation and batch — confirm against the actual product label, because the dosing rationale below depends on it.

How it works for fertility. DHA is the single most abundant polyunsaturated fatty acid in the sperm plasma membrane, concentrated in the midpiece and flagellum, where its high degree of unsaturation sets the membrane fluidity that capacitation, the acrosome reaction, and flagellar beat (motility) all depend on. That same fatty acid is built into cardiolipin in the inner mitochondrial membrane of the sperm midpiece, and cardiolipin's acyl-chain composition governs how efficiently the respiratory chain runs — the direct ATP supply that powers motility, so this is a mitochondrial-function compound at the structural level, not just a supportive one. A 2026 molecular scoping review lays out this membrane-fluidity/cardiolipin mechanism in detail [176], and is upfront that it's built mainly on mechanistic and animal models, with human interventional findings still heterogeneous — an honest gap, and exactly why the human RCT data below carries the real weight. On the oxidative-stress side, a human RCT found seminal EPA/DHA concentrations tracked positively with seminal-plasma antioxidant enzyme activity (superoxide-dismutase-like and catalase-like), which in turn tracked positively with sperm count, motility, and morphology [168] — a clean, plausible route to limiting lipid peroxidation and oxidative sperm-DNA damage, which matters if spermatogenesis restarting after prolonged TRT suppression is running on elevated baseline oxidative stress. That specific link hasn't been tested in a Klinefelter or post-TRT population, but the mitochondrial and antioxidant pathways it runs through are both real, well-mapped fertility levers, and the logic holds.

The evidence. This is one of the better-evidenced compounds in the stack, and the pathway logic above isn't just theoretical — it shows up in outcomes. Two meta-analyses pooling multiple RCTs found omega-3 supplementation improved sperm concentration, motility, and morphology [167, 192], and a dietary RCT built around omega-3-rich nuts moved the same parameters in the same direction [172] — evidence that doesn't require an exotic delivery method, just consistent intake. Observational cohorts tracking dietary omega-3/fish intake against semen quality mostly point the same way [173, 174], though one cohort came back null [175] — worth naming plainly rather than cherry-picking, and it doesn't overturn the RCT and meta-analytic signal sitting above it, especially with a checkable mitochondrial and antioxidant mechanism underneath it. Layered on top, [168] ties the effect to that specific, measurable biological mechanism — antioxidant enzyme activity — which is what earns this compound "strong" rather than just "promising": a real pathway, not just a correlation.

💊 Why this dose. No trial ran the exact ZinZino/AquaOmega branded product — the target below is a rationale built from the RCTs that produced real gains, not a citation to the branded product itself. Across trials that hit significant sperm-parameter improvements, doses ranged from DHA alone at 0.5-2 g/day [169] up to combined EPA+DHA at 1.84 g/day [168, EPAX 5500TG], with lower DHA doses (350-465 mg, 1-3x/day) also working when paired with antioxidant co-factors [171; 170 with vitamin E]. Practical target: dial the branded product, by its own label, to land around 1.8 g/day combined EPA+DHA — matching [168], the trial closest to a true marine EPA+DHA blend and the one with the clearest mechanistic tie to the antioxidant pathway. Duration matters more than precision on the dose: benefits showed up at 12, 14, and 32 weeks across these trials, which lines up with the ~74-day human spermatogenic cycle plus epididymal transit — membrane and mitochondrial remodeling takes a full cycle, so give it at least one, a minimum of ~90 days of consistent daily dosing, before judging response on a semen analysis. Since [170] found the clearest benefit in the DHA+vitamin E arm specifically, pairing omega-3 with an antioxidant already in the stack is a smart, evidence-aligned move that reinforces the same oxidative-stress pathway from two directions — not a proven independent effect of omega-3 alone, but a reasonable bet given what's already sitting next to it in the protocol. Oral is the only route that makes sense for a dietary fatty acid, and it's the only route studied.

Running it smart. Fish oil at these doses (up to ~3 g/day combined EPA+DHA) is well tolerated across the trials — worst case is mild GI upset or a fishy aftertaste, a low price for a compound doing real work on the mitochondrial and antioxidant side. Two things worth actually managing: omega-3s have mild antiplatelet activity, so flag it if anticoagulants or antiplatelets are in the picture, and if a microTESE is anywhere on the horizon, review timing with the surgeon and plan to pause around the procedure per their protocol. And buy quality — a third-party-tested marine oil checked for oxidation/rancidity and heavy-metal purity, because degraded fish oil delivers lipid-peroxidation products and works directly against the antioxidant rationale that's the whole reason it's in the stack.

Ashwagandha KSM-66 (Withania somnifera root extract) 🔵 SUPPORTED

Protocol: 600 mg daily · oral

🎯 Ashwagandha earns its place because it hits the single most modifiable driver of sperm DNA damage and poor motility head-on: oxidative stress. It directly lowers seminal reactive oxygen species and lipid peroxidation, protecting the germ line at the tissue level, and it carries more human semen-parameter data than almost anything else in this category. That's the piece of the stack built to protect the antioxidant capacity a stressed reproductive system burns through, independent of whatever the hormonal axis is doing — which is exactly why it holds up in a TRT-suppressed setting where the axis isn't behaving normally anyway. On top of that, ashwagandha is a genuine anti-stress adaptogen, and chronic stress is a well-established suppressor of the HPG axis and semen quality — so this compound is covering two real upstream fertility levers at once, oxidative stress and the stress axis, not just chasing a sperm number. That's a confident, well-earned reason to run it.

What it is. A standardized, full-spectrum, water-extracted root extract of Withania somnifera (ashwagandha), the Ayurvedic adaptogen with the deepest human fertility dataset of any herbal in this stack. "KSM-66" is a specific proprietary extraction (Ixoreal Biomed) standardized to ≥5% withanolides — a more concentrated, better-characterized animal than the crude root powder used in most of the older fertility literature, so gram-for-gram it's not the same compound.

How it works for fertility. Ashwagandha works two ways, and both map onto known fertility levers. The one that matters most here is direct germ-cell protection against oxidative stress — the single most modifiable driver of sperm DNA damage and poor motility, and the mechanism where antioxidant capacity translates straight into protecting the germline: ashwagandha lowers seminal reactive oxygen species and lipid peroxidation, cuts sperm apoptosis, and restores the antioxidant vitamins (A, C, E) and trace metals (Cu, Zn, Fe) that run depleted in infertile men ([179]; [180]; [182]). That mechanism acts on the tissue itself, downstream of whatever the hormonal axis is doing — which is exactly why it holds up in a TRT-suppressed context: oxidative protection of sperm DNA and motility doesn't need the axis to be intact to matter. The second mechanism runs through the stress axis: in the Lucknow-group trials, ashwagandha raised LH and testosterone and lowered FSH and prolactin, likely through an anti-stress / GABA-mimetic pathway that calms cortisol output rather than direct testicular stimulation ([185]) — and chronic stress is a well-established suppressor of the HPG axis (GnRH -> LH/FSH -> testosterone) and of semen quality generally, so an adaptogen that turns that down is pulling a real fertility lever. Worth being precise: that axis effect was shown in men with an intact hypothalamic-pituitary-testicular loop and stress- or oxidative-linked infertility — not in Klinefelter men on long-term exogenous TRT, where gonadotropin suppression comes from exogenous-testosterone negative feedback, a different mechanism entirely. There's no human data on ashwagandha in TRT-suppressed or XXY physiology, so the axis-modulation story is the bonus here, not the anchor — the germ-cell antioxidant effect is the anchor, and that one travels regardless of what the axis is doing.

The evidence. The human fertility signal is real and consistent across multiple research groups, even though the RCT base underneath it is thin — worth saying plainly rather than dressing up. The single placebo-controlled fertility RCT is [177] (46 oligospermic men, 675 mg/day full-spectrum root extract for 90 days): sperm count up 167%, semen volume up 53%, motility up 57%, with hormone gains well beyond placebo. That result is backed by a cluster of controlled and single-arm pre/post trials from one Indian research group ([179], [180], [181], [182] — roughly 60-180 subjects each, 5 g/day crude root powder), all showing the same pattern: better sperm count and motility, lower seminal oxidative stress, better antioxidant status, better reproductive hormones. A triple-blind active-comparator RCT ([183], n=100) found ashwagandha statistically indistinguishable from pentoxifylline on sperm parameters — solid company to keep. The calibration point is the meta-analysis [178]: with only one true RCT to pool, it couldn't run a full RCT meta-analysis, but the pooled observational data still showed meaningful gains (sperm concentration +13.57 million/mL, motility +8.50%, 14% pregnancy rate), and the authors are upfront that the field needs bigger trials — a call for more evidence, not a mark against what already exists. Narrative reviews ([186], [188]) rate it "moderate" evidence for raising testosterone and improving semen parameters, and [184] notes some animal studies found reversible anti-fertility effects depending on preparation and dose — a real input for dosing discipline, not a reason to leave it out. Two things worth being straight about: every one of these studies enrolled men with an intact HPG axis and oxidative- or stress-linked infertility, none in TRT-suppressed or Klinefelter men, so this protocol is extending a well-established mechanism — oxidative-stress reduction at the germ-cell level — into new territory rather than replaying a proven result, and that mechanism doesn't require an intact axis to work, which is exactly the case for including it here; and there's no registered male-infertility RCT on ClinicalTrials.gov, so no bigger confirmatory trial is already in flight. Net: a real, repeated human signal on sperm parameters resting on one solid placebo RCT plus a strong supporting cluster, anchored by a germ-cell antioxidant mechanism that's fertility-relevant on its own terms even before the sperm-count data is counted — moderate evidence, and moderate is a fair, confident place for a compound this well-tolerated to sit while it does its antioxidant job.

💊 Why this dose. No trial has tested KSM-66 specifically at 600 mg/day for sperm outcomes — this dose is a reasoned bridge between two real datasets, not a direct fertility citation, and that's worth saying straight. The fertility literature runs two regimens: 675 mg/day of a full-spectrum root extract ([177], the only placebo RCT with sperm endpoints — within about 11% of this dose, and the closest real match, though the paper doesn't confirm the KSM-66 brand) and 5,000 mg/day of crude root powder (the Lucknow series). That raw-mass gap looks large, but crude powder and a ≥5%-withanolide standardized extract aren't equivalent gram-for-gram, so the real phytochemical gap is smaller than the numbers suggest. What is directly validated at this exact dose is the product itself: KSM-66 at 300 mg twice daily (600 mg/day) produced a significant testosterone increase in an 8-week placebo RCT in healthy resistance-training men (+96.2 vs +18.0 ng/dL, p=0.004) ([187]) — different population, different endpoint, but real confirmation that this exact dose of this exact extract does something hormonally, which lines up with the stress-axis pathway this compound is leaning on. Put together: 600 mg/day KSM-66 is a well-tolerated dose matched to a real placebo RCT for the testosterone/adaptogen effect, sitting just under the only placebo fertility RCT's dose for the antioxidant/semen-quality mechanism — a defensible middle ground that's doing real work on both pathways, not a tested sperm-outcome dose.

Running it smart. Across the human trials — up to 5 g/day of root powder or ~675 mg/day of extract for 90 days — nobody reported significant adverse effects, and 600 mg/day of a standardized extract sits comfortably inside that range. A few things to actually watch: ashwagandha can raise thyroid hormone output, so if you're on thyroid medication or run hyperthyroid, keep an eye on it; it has mild blood-pressure- and blood-sugar-lowering effects, worth knowing if you're stacking other things that do the same; and it has real immune-stimulating activity, so go in with eyes open if you have an autoimmune condition. Rare hepatotoxicity case reports exist in the broader literature, and animal data show spermicidal effects are possible at high doses depending on preparation — both good reasons to run the dose as written rather than freelancing upward. Given this sits inside a multi-compound stack alongside long-term TRT, pulling baseline and periodic liver-function and thyroid panels is just good practice — cheap insurance, not a red flag from the trial data itself.

References (192)

1. Peptide bioregulation of aging: results and prospects (2009). link

2. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers (2022). link

3. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters (2023). link

4. Molecular mechanism of interaction between oligopeptides and double-stranded DNA (2006). link

5. [Efficacy of peptide bioregulators of vessels in lower-limb chronic arterial insufficiency treatment in old and elderly people] (2014). link

6. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging] (2014). link

7. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis] (2016). link

8. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the CNS in remission] (2015). (cited across: Vesugen, Pinealon) link

9. [Comparative analysis of different methods of geroprotection] (2016). (cited across: Vesugen, Pinealon) link

10. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging (2006). link

11. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: 15-year follow-up (2011). link

12. Peptides of pineal gland and thymus prolong human life (2003). link

13. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people (2004). link

14. [Normalizing effect of pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people] (2007). link

15. [The pineal gland's peptide factors and the rhythms of functions of the thymus and bone marrow in animals during aging] (2004). link

16. [Regulating effect of pineal gland peptides on development of T-lymphocytes in CBA aging mice] (2003). link

17. [Peptide correction of age-related pineal disturbances in monkeys] (2003). link

18. High endogenous melatonin concentrations enhance sperm quality and short-term in-vitro melatonin exposure improves aspects of sperm motility (2010). [melatonin-the-hormone, not the peptide] link

19. Decreased melatonin levels and increased advanced oxidation protein products in seminal plasma related to male infertility (2016). link

20. Seasonal fluctuation in melatonin secretion is not associated with alterations in sperm DNA damage (2017). [negative counterpoint] link

21. Ameliorative effect of melatonin on apoptosis, DNA fragmentation, membrane integrity and lipid peroxidation of spermatozoa in idiopathic asthenoteratospermic men: in vitro (2020). link

22. Pinealon increases cell viability by suppression of free-radical levels and activating proliferative processes (2011). link

23. Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture (2011). [Ki-67 stimulation attributable to epithalon/KED, not Pinealon] link

24. Short peptides stimulate serotonin expression in cells of brain cortex (2014). link

25. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in-vitro interaction with deoxyribooligonucleotides and DNA (2011). link

26. [Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades] (2012). [only Pinealon human dose anchor: 0.2 mg/day] link

27. [The peptide correction of neurotic disorders among professional truck-drivers] (2012). link

28. [Approaches to improving efficacy of health-resort treatment of women with pelvic inflammatory diseases] (1994). [author indexed as 'Khabinson VKh', a typo for Khavinson] link

29. [Functional morphology of peripheral endocrine glands after thymic polypeptide administration in secondary immunodeficiency] (1991). [testis: mild negative/steroidogenic-suppression signal] link

30. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells (2020). link

31. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease (2022). link

32. Report on the Results of Clinical Study of Peptide Bioregulator Cerluten (2003-2004). Manufacturer/vendor document — non-peer-reviewed, sponsor-conflicted; not evidence. link

33. Tissue-specific effects of peptides (2001). [Cortagen — distinct molecule from Cerluten] link

34. Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia (2011). link

35. Effects of bioactive tetrapeptides on free-radical processes (2007). link

36. Epigenetic modification under the influence of peptide bioregulators on 'old' chromatin (2023). link

37. Influence of adding zinc arginyl-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in patients with impaired sperm parameters (2022). [only human semen-endpoint trial; n=98, open-label] link

38. [Polypeptide prostatilen in the treatment of patients with complicated prostatitis] (2004). link

39. [Immunochemical determination of organ-specific ejaculate proteins in differential diagnosis of chronic inflammatory diseases of the male reproductive system] (1997). link

40. [Effect of prostate-derived complex peptide preparations on erectile function in patients with chronic prostatitis] (2026). [single-arm before/after, n=50 — NOT an RCT] link

41. [Validation of the use of prostatilen and testilin for treating male infertility] (1995). [animal, direct-spermatogenesis signal] link

42. [Prophylactic use of prostatilen in rats prior to +Gz loads to reduce changes in urogenital organs] (1997). link

43. [Effect of prostatilen AC suppositories on course of experimental prostatitis] (2012). link

44. [Effect of biologically active substances of animal and plant origin on prooxidant-antioxidant balance in rats with experimental prostatic hyperplasia] (2006). link

45. [Our experience in the use of prostatilen in urology] (2003). link

46. [Polypeptide influence on tissue cell-culture regeneration of various-age rats] (2015). link

47. Prostatilen (prostate extract) product information — dosage and administration (2026). Vendor page — used for dose/route reference only, not evidence. link

48. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties (2025). link

49. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025). [correction: PMID 41240216] link

50. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (2003). link

51. Peptide promotes overcoming of the division limit in human somatic cells (2004). link

52. Effect of regulatory peptides on gene transcription (2003). link

53. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes (2022). [female germ cell; non-linear dose-response] link

54. Epitalon-activated telomerase enhances bovine oocyte maturation rate and post-thawed embryo development (2025). [female germ cell] link

55. Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age (1989). link

56. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis (2024). [86% vs 40% spermatogenesis; FSH dose median 412.5 IU/wk, IQR 225-450] link

57. Gonadotropin Treatment for Male Hypogonadotropic Hypogonadism (2021). link

58. Efficacy of follitropin-alpha versus human menopausal gonadotropin for male patients with congenital hypogonadotropic hypogonadism (2019). link

59. Gonadotropin treatment for male partial congenital hypogonadotropic hypogonadism in Chinese patients (2020). link

60. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone (2002). link

61. Pulsatile GnRH or hCG/hMG as effective treatment for men with hypogonadotropic hypogonadism: review of 42 cases (1998). link

62. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism (1985). link

63. Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids (2025). link

64. Does hormonal therapy improve sperm retrieval rates in men with non-obstructive azoospermia: systematic review and meta-analysis (2022). [hypergonadotropic subgroup OR 1.73, P=0.43 — no significant benefit] link

65. Outcome of testicular sperm extraction in nonmosaic Klinefelter syndrome patients: what is the best approach? (2015). link

66. Low-dose hCG maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression (2005). [RCT, surrogate ITT endpoint] link

67. Concomitant intramuscular hCG preserves spermatogenesis in men undergoing testosterone replacement therapy (2013). link

68. The Use of hCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use (2015). link

69. Endocrine stimulation in men with non-obstructive azoospermia and low serum testosterone prior to micro-TESE: hormonal response as a predictor of sperm retrieval (2026). link

70. Novel insights on testicular volume and testosterone replacement therapy in Klinefelter patients undergoing testicular sperm extraction: retrospective clinical study (2018). link

71. Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta-Analysis (2024). [adjacent population — HH, normal testes] link

72. Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism — Systematic Review and Meta-Analysis (2026). link

73. Use of Human Chorionic Gonadotropin (hCG) or hCG-Combined Treatments in Male Infertility: A Systematic Review (2025). link

74. Exogenous testosterone: a preventable cause of male infertility (2013). [most TRT-induced azoospermia recovers within ~1 year off testosterone — causal confound] link

75. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone (2015). link

76. Oral enclomiphene citrate stimulates endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel (2013). link

77. Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study (2023). link

78. Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies (2025). link

79. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice (2015). link

80. Clomiphene citrate for male infertility: a systematic review and meta-analysis (2023). [positive] link

81. Empirical hormonal treatments for idiopathic male infertility: a network meta-analysis comparing antiestrogens and FSH (2025). [best-supported regimen 25 mg EOD; inverse SERM dose-response] link

82. Pharmacological non-hormonal treatment options for male infertility: a systematic review and network meta-analysis (2024). [clomiphene not significantly different from placebo for sperm concentration] link

83. Clomiphene citrate and hCG before microdissection TESE in non-obstructive azoospermia: retrospective non-randomized series (2026). [25 mg/day + hCG, NULL on retrieval: 45% vs 50%, p=0.53] link

84. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism (2019). link

85. Enclomiphene citrate for the treatment of secondary male hypogonadism (2016). link

86. Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism (2013). link

87. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men (2019). link

88. Kisspeptin responsiveness signals emergence of reproductive endocrine activity: implications for human puberty (2016). link

89. Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men (2017). link

90. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men (2026). [very recent, n=3; documents desensitization] link

91. Potential Clinical Use of Kisspeptin (2015). link

92. Intratesticular action of kisspeptin in rhesus monkey (Macaca mulatta) (2013). link

93. GnRH-deficient phenotypes in humans and mice with heterozygous variants in KISS1/Kiss1 (2011). link

94. Kisspeptin and its effect on mammalian spermatogenesis (2019). link

95. Testosterone supplementation rescues spermatogenesis and in-vitro fertilizing ability of sperm in Kiss1 knockout mice (2020). [operative lever is downstream testosterone/LH] link

96. Kisspeptin as a marker for male infertility: comparative study of serum and seminal plasma kisspeptin between fertile and infertile men (2025). [higher kisspeptin in infertile men — contradictory signal] link

97. Randomized Phase 2a study of TAK-448 (kisspeptin analog) administered intermittently in middle-aged and older men with low testosterone (2015-2016). ClinicalTrials.gov NCT02381288. [excluded Klinefelter patients] link

98. Elamipretide as a potential candidate for relieving cryodamage to human spermatozoa during cryopreservation (2020). [ex-vivo cryoprotection, not a fertility study] link

99. Antioxidant effect of Elamipretide on bull sperm cells during the freezing/thawing process (2021). link

100. Elamipretide enhances post-thaw rooster sperm quality by mitigating oxidative stress and optimizing mitochondrial function during cryopreservation (2025). [toxicity ceiling at 12 umol/L] link

101. Mitochondrial dysfunction and ER stress induced by PPARalpha activation led testicular apoptosis in SD rats exposed to DEHP (2023). link

102. Mitochondrial Metabolic Checkpoints in Human Fertility: Reactive Oxygen Species as Gatekeepers of Gamete Competence (2026). link

103. TAZPOWER — Phase 2/3 randomized crossover trial of subcutaneous elamipretide in genetically confirmed Barth syndrome, with open-label extension (2021). ClinicalTrials.gov NCT03098797. [40 mg SC daily; non-reproductive] link

104. MMPOWER-3 — Phase 3 randomized placebo-controlled trial of daily subcutaneous elamipretide in primary mitochondrial myopathy, with open-label extension (2020). ClinicalTrials.gov NCT03323749. link

105. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study (2024). [single 10 mg local bladder injection] link

106. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (2025). link

107. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing (2025). link

108. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management (2026). link

109. BPC 157 and blood vessels (2014). link

110. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft-tissue healing (2019). link

111. A new gastric juice peptide, BPC: overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC (1993). [carries 'Testis' in MeSH indexing but no testicular intervention data] link

112. Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02 (BPC-157) (2015-2016). ClinicalTrials.gov NCT02637284. [oral, n=42, no results posted] link

113. Randomized Phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain (2026). ClinicalTrials.gov NCT07437547. link

114. Comparative expression and regulation of TMSB4X in male reproductive tissues of rats and chickens (2013). [gene-expression only, not an intervention] link

115. Cloning and characterization of a testis-specific thymosin beta-10 cDNA: expression in post-meiotic male germ cells (1991). [thymosin beta-10, family background] link

116. The effect of thymosin treatment of venous ulcers (2010). [full-length Tβ4, not TB-500] link

117. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective randomized study on safety, tolerability, and healing enhancement (2007). link

118. Randomized, double-blind, placebo-controlled dose-response study of the safety and efficacy of thymosin beta-4 in the treatment of pressure ulcers (2006). ClinicalTrials.gov NCT00382174. [topical Tβ4 only] link

119. L-carnitine and L-acetylcarnitine supplementation for idiopathic male infertility (2020). [most rigorous review; no pregnancy benefit] link

120. Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review (2007). link

121. Effects of carnitine and coenzyme Q10 on sperm quality and pregnancy rates in men with unexplained infertility: a systematic review and network meta-analysis (2025). link

122. Influence of oral vitamin and mineral supplementation on male infertility: a meta-analysis and systematic review (2019). link

123. The efficacy of combined L-carnitine and L-acetyl carnitine in men with idiopathic oligoasthenoteratozoospermia: a systematic review and meta-analysis (2019). link

124. The effect of antioxidants on sperm quality parameters and pregnancy rates for idiopathic male infertility: a network meta-analysis of RCTs (2022). [no pregnancy benefit] link

125. The efficacy of antioxidants in sperm parameters and ROS during the freeze-thaw process: a systematic review and meta-analysis (2020). [DNA/ROS reductions driven by other antioxidants, not carnitine] link

126. The Effect of Nutrients and Dietary Supplements on Sperm Quality Parameters: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2018). (cited across: L-Carnitine, Ubiquinol, Omega-3) link

127. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial (2006). [negative RCT] link

128. Use of carnitine therapy in selected cases of male-factor infertility: a double-blind crossover trial (2003). link

129. A placebo-controlled double-blind randomized trial of combined L-carnitine and L-acetyl-carnitine in men with asthenozoospermia (2004). link

130. L-carnitine improves sperm acrosin activity in male infertility patients (2018). link

131. Yihechun capsules combined with levocarnitine for oligozoospermia and asthenospermia (2020). link

132. Metabolism and action of L-carnitine: its possible role in sperm tail function (1992). link

133. Cotransporting ion as a trigger for cellular endocytosis of transporter-targeting nanoparticles: SLC22A5 (OCTN2)-mediated carnitine-conjugated nanoparticles for oral drug delivery (2017). link

134. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial (2008). link

135. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men (2009). [see Expression of Concern, ref 136] link

136. Expression of Concern: Efficacy of Coenzyme Q10 on Semen Parameters... in Infertile Men (2023). [J Urol, 2023-01-10] link

137. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo-controlled, randomized study (2012). [only reduced-form-specific RCT; see Expression of Concern, ref 138] link

138. Expression of Concern: Effects of the Reduced Form of Coenzyme Q10 (Ubiquinol) on Semen Parameters in Men with Idiopathic Infertility (2023). [J Urol, 2023-01-10] link

139. Coenzyme Q10 improves seminal oxidative defense but does not affect semen parameters in idiopathic OAT: a randomized double-blind placebo-controlled trial (2011). link

140. Effect of coenzyme Q10 supplementation on antioxidant enzyme activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial (2013). link

141. Coenzyme Q10 and male infertility: a meta-analysis (2013). [positive pooled effect majority-built on the now-flagged Safarinejad 2009 dataset] link

142. The Effect of Dietary Supplements on Male Infertility in Terms of Pregnancy, Live Birth, and Sperm Parameters: A Systematic Review and Meta-Analysis (2025). [negative on hard outcomes] link

143. Effect of Antioxidants on Sperm Quality Parameters in Subfertile Men: A Systematic Review and Network Meta-Analysis of RCTs (2023). link

144. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease (2004). [tolerability anchor for high dose] link

145. L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial (2018). link

146. Coenzyme Q10, oxidative stress, and male infertility: a review (2021). link

147. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility (1993). [only dose/route-matched human RCT; n=20, varicocele/inflammation] link

148. Glutathione treatment of dyspermia: effect on the lipoperoxidation process (1994). link

149. PHGPx and spermatogenesis (2001). link

150. X-ray fluorescence microscopy reveals the role of selenium in spermatogenesis (2009). link

151. The systemic availability of oral glutathione (1992). [oral bioavailability very low] link

152. Comparison of the effect of a combination of eight micronutrients versus a standard mono preparation on sperm parameters (2016). [8-ingredient formula, not glutathione monotherapy] link

153. Dietary supplementation with a novel L-carnitine multi-micronutrient in idiopathic male subfertility (oligo-, astheno-, teratozoospermia): a randomized clinical study (2020). [combination formula] link

154. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia (2017). link

155. Vitamin D3 supplementation effects on spermatogram and oxidative-stress biomarkers in asthenozoospermic infertile men: a randomized, triple-blind, placebo-controlled clinical trial (2021). [4,000 IU/day; positive on motility] link

156. The effects of vitamin D3 supplementation on spermatogram and endocrine factors in asthenozoospermic infertile men: a randomized, triple-blind, placebo-controlled clinical trial (2021). link

157. Evaluation of the effect of vitamin D supplementation on spermatogram and seminal/serum oxidative-stress indices in asthenospermic infertile men: study protocol for a triple-blind RCT (2021). link

158. Vitamin D and Male Reproduction: Updated Evidence Based on Literature Review (2022). link

159. Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial (2018). [largest/most rigorous; NULL on primary semen endpoint] link

160. Effect of vitamin D supplementation on testosterone levels in men (2011). link

161. Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial (2017). [no testosterone effect] link

162. Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial (2018). link

163. Serum 25-hydroxyvitamin D and sperm DNA fragmentation index in men referred for infertility: a cross-sectional study of 783 patients (2025). [no 25(OH)D-DFI association; lower-tier journal — weight lightly] link

164. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men (1998). [K2/D companion rationale] link

165. Vitamin D Supplementation and Male Infertility: The Copenhagen Bone-Gonadal Study — a double-blinded randomized clinical trial (2011). ClinicalTrials.gov NCT01304927. link

166. A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for Men With Oligoasthenoteratozoospermia (RA-2) — calcitriol sub-arm (2014). ClinicalTrials.gov NCT02061384. [explicitly excludes Klinefelter and Y-microdeletion men] link

167. The Effect of Omega-3 Fatty Acids, EPA, and/or DHA on Male Infertility: A Systematic Review and Meta-analysis (2018). [sperm concentration NOT significant; extreme heterogeneity I2 76-98%] link

168. Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic antioxidant capacity of seminal plasma in infertile men with idiopathic OAT: a double-blind, placebo-controlled, randomised study (2010). link

169. Effect of dietary supplementation with a highly pure and concentrated DHA supplement on human sperm function (2018). [no DNA-fragmentation benefit] link

170. Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial (2020). [benefit tied to DHA+vitamin E, not DHA alone] link

171. Docosahexaenoic acid in the treatment of idiopathic male infertility (2019). link

172. Effect of nut consumption on semen quality and functionality in healthy men consuming a Western-style diet: a randomized controlled trial (2018). [whole-food plant ALA, NOT marine EPA/DHA] link

173. Dietary fat and semen quality among men attending a fertility clinic (2012). [observational] link

174. Fatty acid intake in relation to reproductive hormones and testicular volume among young healthy men (2017). [observational] link

175. Fatty acids, food groups and semen variables in men referring to an Italian fertility clinic: cross-sectional analysis (2020). [higher PUFA intake associated with LOWER sperm concentration] link

176. Nutritional modulation of male fertility: a molecular-focused scoping review (2026). [high PMID/2026 date but verified real] link

177. Clinical Evaluation of the Spermatogenic Activity of the Root Extract of Ashwagandha (Withania somnifera) in Oligospermic Males: A Pilot Study (2013). [the one small placebo RCT, n=46] link

178. Withania somnifera (Indian ginseng) in male infertility: an evidence-based systematic review and meta-analysis (2018). [calls evidence 'too limited to provide robust evidence'] link

179. Withania somnifera improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males (2010). link

180. Withania somnifera improves semen quality by combating oxidative stress and cell death and improving essential metal concentrations (2011). link

181. Withania somnifera improves semen quality in stress-related male fertility (2011). link

182. Efficacy of Withania somnifera on seminal plasma metabolites of infertile males: a proton NMR study at 800 MHz (2013). link

183. Comparative evaluation of the effects of Withania somnifera with pentoxifylline on sperm parameters in idiopathic male infertility: a triple-blind randomised clinical trial (2018). link

184. Effects of Withania somnifera on the Reproductive System: A Systematic Review of the Available Evidence (2018). [notes reversible animal anti-fertility effects] link

185. Role of Withania somnifera (Ashwagandha) in the management of male infertility (2018). link

186. Beyond tribulus (Tribulus terrestris L.): the effects of phytotherapics on testosterone, sperm and prostate parameters (2019). link

187. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial (2015). [dose-matched to 600 mg KSM-66 but measured testosterone/strength, not fertility] link

188. Botanicals in health and disease of the testis and male fertility: a scoping review (2022). link

189. [Comparative analysis of different methods of geroprotective] link

190. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission] link

191. The Effect of Nutrients and Dietary Supplements on Sperm Quality Parameters: A Systematic Review and Meta-Analysis of Randomized Clinical Trials link

192. The Effect of Nutrients and Dietary Supplements on Sperm Quality Parameters: A Systematic Review and Meta-Analysis of Randomized Clinical Trials link

For informational and entertainment purposes only.